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Abstract 
Rheumatoid- and psoriatic arthritis (RA and PsA) are the two most prevalent 
inflammatory joint diseases in Caucasian. Different biomarkers in peripheral blood 
may contribute in the diagnostic and prognostic process, as well as in assessing the 
disease activity of the individual patient. The concentration of the leukocyte protein 
complex calprotectin (S100A8/A9) is increased in inflamed joints and in peripheral 
blood of patients with various inflammatory diseases. S100A12 is another S100 
protein that more recently has been described as a proinflammatory protein in 
arthritis. Disease manifestations and prognosis in RA and PsA have both articular and 
non-articular aspects, and these should be adressed during treatment of the patients. 
The risk of cardiovascular disease is increased in RA, and to a lesser extent in PsA. 
Supplementation with fish oil has modest beneficial effects in RA both for arthritis 
and collateral health.  
The overall aim of the study was to investigate calprotectin and S100A12 as 
biomarkers of disease activity or distinct clinical features in patients with either RA 
or PsA. In addition, we wanted to estimate the prevalence of PsA in our population 
and to explore effects of short-term oral supplementation with seal oil. 
We found a prevalence of PsA in the county of Hordaland equivalent to 1.95 per 
1000. If given a prevalence of psoriasis at 1.4%, this corresponds to a PsA prevalence 
among psoriatics of 14%. The levels of calprotectin were elevated in stool samples 
from patients with PsA, suggesting asymptomatic psoriatic enteropathy. In a clinical 
trial with seal oil to patients with PsA we found improvement in subjective measures 
and a significant shift in the fatty acid composition in peripheral blood, toward a 
putative antiinflammatory profile. We found that both calprotectin and S100A12 
levels in serum correlate with disease activity parameters in RA. High levels of 
S100A12 were detected in patients with RA, as well as new conformational states of 
this protein. The S100 proteins did not perform better than CRP as inflammatory 
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biomarkers in patients with PsA, but the serum levels of calprotectin and S100A12 
were associated with peripheral radiographic features of arthritis.  
The serum levels of calprotectin and S100A12 were higher in patients with RA than 
in those with PsA, supporting the concept of RA as a more systemic inflammatory 
disease than PsA. Elevated levels of S100A12 may have prognostic implications in 
RA since we found associations to the presence of rheumatoid factor, anti-CCP and 
extra-articular manifestations, which are known risk factors for joint destruction and 
cardiovascular events in these patients.  
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1. General introduction 
Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are the two most incident 
chronic inflammatory joint diseases in Caucasian (1). Previously, both diseases were 
classified as RA. The observation that psoriasis was more frequently seen in patients 
with inflammatory joint disease and that these patients had some common disease 
characteristics, led to the recognition of PsA as a distinct disease entity (2). 
1.1 Rheumatoid arthritis 
The prevalence of RA is 2 per 1000 men and 7 per 1000 women according to the 
Oslo RA-register (3). RA is characterised by a chronic inflammation of synovial 
joints like the wrists and the proximal finger joints, and leads to progressive joint 
erosions. In addition to stiffness, pain and loss of function, patients have increased 
morbidity (4) and mortality, the latter has also been studied in Norwegian RA 
populations (5,6). Cardiovascular disease (CVD) is responsible for the majority of the 
excess mortality in RA (7), and the main cause of CVD in RA is atherosclerosis. A 
recent review of this field is recently published in Norwegian by Hollan et al (8).  
Most studies of RA use the criteria from the American College of Rheumatology 
(ACR), formerly the American Rheumatism Association (9). These criteria consist of 
clinical (morning stiffness, symmetric synovitis of hands and in three or more joint 
areas, rheumatoid nodules), laboratory (rheumatoid factor) and radiographic 
(erosions) characteristics. Erosions develop early and are associated with irreversible 
deformities, but early treatment with disease-modifying antirheumatic drugs 
(DMARDs) improves outcome (10) and reduces mortality from RA (11). However, 
there are subgroups of patients with a good prognosis that should not be over-treated, 
thus there is a need for predictors for outcome giving basis for individual treatment 
decision-making. Several prognostic factors are identified (12), but still the disease 
 12 
outcome of an individual patient with early RA is difficult to predict. Some blood 
tests are useful in both the diagnostic and predictive process of RA: 
 C-reactive protein (CRP) reflects the inflammatory activity of RA, and time-
integrated CRP correlates with radiographic progression of the joint destruction 
(13,14). Also a single analysis of CRP may predict radiographic outcome (15,16). 
 Rheumatoid factors (RF) are antibodies against the Fc portion of immunoglobulin 
(Ig) G (17), and may themselves be of IgM, IgG or IgA class. A positive test for 
IgM RF is detected in about 70% of patients with RA, but also in other rheumatic 
and in infectious diseases. There is high correlation between RF titer and erosion 
scores, and the ”highest value ever” for serum RF is still regarded the best 
laboratory predictor of disease severity (18).   
 Anti-CCP (anti-citrullinated cyclic peptide) antibodies target proteins where 
arginine has been replaced by citrulline. Citrullination represents the calcium-
dependent conversion of peptidylarginin to peptidylcitrulline. This normally 
occurs, but is enhanced in inflammatory conditions (19). The specificity of this 
test for RA is in the range of 90-98%, while the sensitivity is lower. Anti-CCPs 
predate the clinical disease of RA by several years and a positive test has high 
predictive value for RA in patients with undifferentiated arthritis and for 
radiographic progression in RA (20).  
The anti-CCP test is more specific for RA than is the RF test, and anti-CCPs have 
been increasingly suspected to be pathogenetic in RA through a gene-environment 
interaction (21). The most important genetic risk factor for RA is the presence of a 
series of alleles in the DR-region of HLA (Human Leukocyte Antigen) that share a 
common amino acid sequence (“shared epitope”). This epitope allows the 
presentation of hitherto unknown arthritogenic peptides to T cells (22). A new 
aetiological hypothesis for anti-CCP positive RA suggests that smoking in the context 
of this HLA-DR shared epitope might trigger immunity to citrulline-modified 
proteins that may cause arthritis (21). Activated T-cells access the joints by 
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mechanisms facilitating extravasation such as endothelial cell activation, upregulation 
of cellular adhesion molecules and chemotactic substances (23). S100 proteins seem 
to have a central role in this leukocyte migration (24). The T-cells stimulate 
macrophage release of cytokines like interleukins (IL) IL-1, IL-6, IL-10 and tumour 
necrosis factor alfa (TNF-α) as well as prostaglandins, proteolytic enzymes and other 
proteins which in turn leads to pannus formation, joint destruction and bone 
degradation (25) (figure 1).  
 
 
 
 
 
RA has a variable disease presentation and course, and the assessment of several 
variables is needed to describe the status of the disease. Different sets of endpoint 
measures have been used, including variable numbers of joints to assess. During the 
Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials 
(OMERACT, Maastricht 1992) a core set of disease measures was defined (26). This 
includes the numbers of swollen and tender joints, patient’s assessment of joint pain 
Figure 1. Schematic illustration of the pathogenesis of rheumatoid 
arthritis with pannus formation and joint destruction.   
 From www.bio.davidson.edu/Courses/Immunology 
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and global assessment of disease activity, physician’s global assessment of disease 
activity, acute phase response measure, functional impairment and radiological 
assessment. The development of this core set was followed by the validation of the 
reduced joint count to 28 (27). Based on this, a composite disease activity score 
(DAS28) has been developed (28) and is useful both in clinical practice and trials to 
assess disease activity. This is available as an online tool at 
www.umcn.nl/userfiles/other/dasculators.xls. 
A wide range of extra-articular features (ExRA) may develop in patients with RA, 
including vasculitis, rheumatoid nodules, pericarditis, rheumatoid lung disease, 
Felty’s syndrome, scleritis or episcleritis, neuropathy and secondary Sjögren’s 
syndrome (SS). These manifestations may differ with respect to pathogenesis, 
although vascular mechanisms seem to be shared (29). There is no widely used 
definition of ExRA, but a set of criteria has been developed to identify severe ExRA 
such as pericarditis, pleuritis, cutaneous vasculitis, neuropathy, scleritis, vasculitis 
involving other organs and Felty’s syndrome (30). Patients with severe ExRA have 
increased morbidity and mortality compared to those without (30), and these ExRA 
are recognised as major determinants both of CVD and the excess mortality in RA 
(31).  
In light of similarities between the vascular patology of ExRA and the accelerated 
atherosclerosis seen in RA, the latter has also been referred to as an ExRA (32). 
Epidemiological observations give evidence that mechanisms other than the classic 
atherosclerotic risk factors may play a role in the accelerated atherosclerosis of RA 
(33). RA gives rise to a systemic inflammation as evidenced by increased levels of 
inflammatory markers in blood, and by the presence of ExRA. CRP, RF and 
inflammatory mediators such as TNF-α, IL-1, IL-6 generated in the synovial tissue 
released into circulation may alter the function of distant organs to generate a 
proatherogenic state. This includes endothelial dysfunction, insulin resistance, 
dyslipidemia and a prothrombotic status (34). S100 proteins are also likely to be 
involved in this process (35). 
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1.2 Psoriatic arthritis 
The variability in clinical presentation of PsA is reflected in the classical description 
by Moll and Wright of 5 clinical subclasses (2): 1) Arthritis with predominantly 
involvement of distal interphalangeal (DIP) joints; 2) arthritis mutilans; 3) symmetric 
polyarthritis – indistinguishable from RA; 4) asymmetric oligoarthritis; 5) 
predominantly spondylarthritis. 
  
Previous studies have reported prevalences of PsA at about 1 per 1000 (36). Apart 
from a small study of a Lapp population in Norway (37) and a health interview 
survey of patients with psoriasis (38), to our knowledge epidemiologic studies of PsA 
has not been performed in Norway.  
Spondylarthritis as the predominant feature of PsA is not common, but if 
radiographically assessed, evidence of arthritis of the spine or sacroiliac joints may be 
demonstrated in 20-40% of the patients (39). The spinal predilection seen in PsA, 
ankylosing spondylitis (AS) (synonymous with Bechterew’s disease), arthritis 
associated with inflammatory bowel disease (IBD) and reactive arthritis is the basis 
for the grouping of these diseases into the spondyloarthropathies. In PsA this 
affection tends to be asymmetric and segmental, while symmetric in AS (40). In 
addition to arthritis, inflammatory lesions at the insertion of tendon into bone 
(enthesitis) are common in PsA. Dactylitis or sausage digit is the clinical appearence 
Figure 2.  
Psoriatic arthritis of finger 
joints. Note the affection of 
distal interphalangeal joints 
and shortening of the first  
metacarpophalangeal joint 
(arthritis mutilans). 
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of combined synovitis, tenosynovitis and inflammation of subcutaneous tissue, and 
may occur at some time in approximately 30-40% of patients with PsA (39).  
Another characteristic feature of the spondyloarthropathies is the association to 
enteric inflammation (41), which is striking in patients with arthritis associated to 
IBD and in patients with entero-reactive arthritis. Also in AS and in patients with 
axial PsA endoscopic studies have revealed that up to two thirds of patients may have 
macro- or microscopical inflammatory changes without overt clinical colitis (41,42). 
The disease course of PsA is variable, but is generally more benign than in RA. 
Several patients have self-limiting disease and go into remission (43), but up to 47% 
of the patients have radiographic damage after 2 years (44). A low erytrocyte 
sedimentation rate (ESR) at onset is associated with a mild disease course, while 
polyarticular disease at onset predicts development of clinical deformities and 
radiographic erosive disease (45).  
There are conflicting results concerning mortality in patients with PsA. In a hospital-
based study the mortality was increased with a standardised ratio of 1.62 (46), but in 
a community-based study no excess mortality was found (47). Prevalence ratios for 
CVD and the risk factors diabetes II, hypertension and hyperlipidemia are increased 
in patients with PsA, but less than for RA (48).  
PsA has been defined as “an inflammatory arthritis associated with psoriasis, which is 
usually negative for RF” (2). Seronegativity is not absolute, and several reports show 
that patients with evident PsA even may be postive for anti-CCPs (49,50). At an 
individual basis it may be difficult to distinguish PsA from other inflammatory joint 
diseases in a patient with psoriasis, i.e. RA, AS, IBD-associated arthritis, reactive 
arthritis and inflammatory osteoarthtritis.  
Several additional classification criteria have been proposed and used for PsA, 
including those from the European Spondyloarthropathy Study Group (ESSG) (51). 
Recently, a large international study group (CASPAR) developed new classification 
criteria for PsA (52). To meet the CASPAR criteria, a patient with inflammatory 
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articular disease (joint, spine or entheseal) must have 3 or more of the following 
categories: 1) Psoriasis (current or formerly) or a family history of psoriasis; 2) 
Typical nail changes; 3) Negative RF; 4) Dactylitis (current or formerly); 5) 
Radiographical evidence of juxta-articular new bone formation. Unlike in RA, the 
ESR and CRP are generally not reliable as disease activity parameters in PsA (53), 
and normal levels were reported as a feature with discriminative value toward RA in 
the CASPAR study (52). The observation that inflammatory biomarkers in PsA are 
less elevated than in RA may indicate that PsA is a less systemic inflammatory 
disease than RA. 
PsA is regarded a type I T-cell associated autoimmune disease (54). Although the 
initial events and causes are not understood, the widely accepted concept of “gut-
synovium axis” in spondyloarthropathies hypothesize that naive T-cells are primed 
by bacterial antigens in inflamed gut mucosa, recirculate, are attracted to the 
synovium by different homing mechanisms, reactivate and induce joint inflammation 
(55). The immunohistological features of synovial tissue include infiltration with 
activated T-lymfocytes and neutrophils in a perivascular distribution. T-helper cells 
(CD4+) are the most common lymphocytes, but there are also B-cells. The functions 
of the latter in PsA are unclear since PsA is not associated with autoantibodies (54).  
Hypervascularisation is a prominent feature of the synovitis in PsA (56), and 
angiogenic growth factors such as VEGF (vascular endothelial growth factor) are 
upregulated. Key synovial cytokines, which are less elevated than in RA, favour bone 
resorption. But new bone formation is another radiographic feature of PsA, 
illustrating that bone remodelling is dysregulated (54).  
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1.3 S100 proteins calprotectin and S100A12 
1.3.1 Biochemical and clinical aspects 
Calprotectin is the most abundant cytosolic protein in phagocytic cells, and was 
described in 1980 by Fagerhol et al (57) as the L1 protein, reflecting granulocyte 
turnover in vivo. The name calprotectin was later proposed (58), reflecting both its 
calcium-binding and antimicrobial effects. The protein is involved in intracellular 
signal transduction and exerts regulatory functions in inflammation as reviewed by 
Johne et al (59).  
The concentration of calprotectin is raised in stool samples from patients with IBD, 
and reflects the granulocyte migration through the gut wall (60). Measurement of 
calprotectin in feces is a widely used test in the diagnosis and monitoring of IBD (61) 
and elevated concentrations indicate organic intestinal disorders (62).  
Early studies of patients with RA demonstrated high concentrations of calprotectin in 
synovial fluid (63), in synovial membrane (64) and in plasma (63). The concentration 
of calprotectin in blood reflects disease activity in inflammatory arthritides such as 
RA (65,66), juvenile chronic arthritis (67), reactive arthritis (68) and in PsA (69,70). 
Also in systemic lupus erythematosus (71) and in polymyalgia rheumatica (72) 
calprotectin seems to be a marker of inflammation. In Sjögren’s syndrome (SS) 
salivary calprotectin correlates with variables of SS glandular pathology (73), 
suggesting that the protein level in saliva may be a marker of the local disease 
activity. Calprotectin has been shown to inhibit protein kinases (74) and inhibit 
avridine-induced arthritis in rats (75), but as outlined, subsequent clinical studies 
have identified calprotectin as a marker of inflammation. Hence it is referred to as a 
proinflammatory protein in arthritis (76).  
Extremely high expression of plasma calprotectin is seen in a syndrome with 
recurrent infections, hepatosplenomegaly, anemia and evidence of systemic 
inflammation (77), while blocking of calprotectin inhibits neutrophil migration (78). 
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Calprotectin is a heterotrimer with one light and two heavy chains non-covalently 
linked, and the molecular mass of the complex is about 36 kilo Dalton (57,79). Other 
groups that have studied calprotectin have given the two subunits different names 
such as cystic fibrosis antigen (80), MRP-8 and MRP-14 (myeloid related protein) 
(64), and calgranulin A and B (81). Referred to as members of the S100 protein 
family, the subunits of calprotectin seem to be identical to S100A8 (L1 light chain) 
and S100A9 (L1 heavy chain), and the functional heterocomplex calprotectin to 
S100A8/A9. Ravasi describes additional designations and genomic aspects of the 
S100 proteins (82). The term S100 protein was introduced because the first members 
of this protein family were soluble in 100% ammonium sulphate solution (83). The 
complex formations of S100A8 and S100A9 are still under discussion. In absence of 
calcium, the heterodimer S100A8/A9 is the preferred form (figure 3), while complex 
formation corresponding to S100A8/A92 is the most likely physiologic conformation 
(57,84).  
 
 
 
Figure 3.   
Model of the crystal 
structure of calprotectin 
(S100A8/A9) as 
determined by x-ray 
diffraction. From the 
Protein Data Bank at 
http://www.rcsb.org/pdb 
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In yeast cells, the tetramer (S100A8/A9)2 has been described as the functional form 
and this has been proposed as the preferred form in humans (85). From extracts of 
arterial plaques additional complexes of S100A8 and S100A9 have been suggested 
(86).  
S100A12 is a more recently described S100 protein (87,88) and is both genetically, 
structurally and functionally related to S100A8 and S100A9 (82). Other designations 
of S100A12 are calgranulin C, MRP-6 and Extra-cellular Newly identified RAGE-
binding protein (EN-RAGE) (82,89), the latter designation reflecting the key receptor 
to which this protein binds. A hexamer of S100A12 (figure 4) is suggested to be the  
 
form that reacts with the Receptor for Advanced Glycation End products (RAGE) 
(90,91). Complex formation between S100A12 and S100A8 or S100A9 has not been 
detected (92). 
As reviewed by Donato (24) the family of S100 proteins comprises 25 or more 
proteins exerting regulatory roles in cytoplasma such as cell proliferation and 
Figure 4.  
Model of the crystal structure of  the 
S100A12 hexamer as determined by 
x-ray diffraction. From the Protein 
Data Bank at http://www.rcsb.org/pdb 
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differentiation, apoptosis, signal transduction and cell motility. This family of 
proteins is a member of the EF-hand superfamily of Ca2+ -binding proteins. The 
binding of Ca2+ by S100 proteins contributes to buffering the cytosolic Ca2+ 
concentration, and may thereby regulate enzyme activity (24,93). Some of the S100 
proteins can be secreted from the cell and exert cytokine-like, mainly 
proinflammatory effects. As discussed later, the binding of Ca2+ leads to changes of 
the three-dimensional structure of the S100 protein, and thus alters its binding 
capacity and function (90).  
Not only calprotectin, but also S100A12 has been found in increased concentrations 
in synovial tissue, synovial fluid and serum from patients with inflammatory arthritis 
(94-98). Associations to clinical disease activity parameters have in some studies 
been stronger for calprotectin than for CRP and ESR, and it has been argued that 
S100 proteins may be superior to conventional inflammatory biomarkers (99). The 
concentrations of S100A8/A9 and S100A12 in synovial fluid from patients with 
arthritis are up to 10 times higher than in serum (63,70). Hence the serum levels have 
been proposed to reflect overflow from activated cells in synovium and synovial fluid 
(76). Alternatively, the origin of calprotectin and S100A12 in serum is release from 
neutrophils on the luminal side of endothelial cells during migration to the 
inflammatory site (95). 
1.3.2 Proinflammatory effects in arthritis 
In the development of arthritis the migration of leukocytes from the circulation to the 
synovium is stimulated by cytokines and chemokines produced by activated 
macrophages and endothelial cells (23). The expressions of both S100A8/A9 (100) 
and S100A12 (101) are increased in activated phagocytes, and after release these 
proteins may have chemotactic effects (95,102). In addition to the release of 
calprotectin by cell death, such release may be induced by other mechanisms as by 
bacterial lipopolysaccharide (103). The binding of S100A8/A9 and S100A12 to 
endothelial cells facilitate transendothelial migration of leukocytes by inducing the 
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expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1 (ICAM-1) and proinflammatory chemokines on endothelium (100). The 
secretion of S100A8/A9 and S100A12 thus facilitates a further inflammatory 
response. The binding site for S100A8/A9 on endothelial cells may be heparan 
sulfate (104) or carboxylated glycans (105), while effects of S100A12 are described 
through binding to RAGE. Stimulation of RAGE by S100A12 or other ligands 
activates inflammatory reactions like the NF-κB system (nuclear factor κB) and 
triggers the secretion of IL-1 and TNF-α from lymphocytes, phagocytes and 
endothelial cells (89). 
In vitro, it has been demonstrated that S100A8/A9 binds specifically to arachidonic 
acid (AA), and there is evidence that this complex may serve as transport-protein to 
deliver AA to target cells (106,107). AA and its metabolites are involved in cell-to-
cell interactions in inflammation and atherosclerosis (108). 
Further roles of S100A8/A9 and S100A12 in synovitis are less described, but 
experimental data indicate a direct role of S100A8 and S100A9 in the destructive 
process of inflammatory arthritis (109), although one study described protective 
effect of calprotectin in experimental arthritis (75). 
Synovial histopathological studies have described higher expression of calprotectin in 
synovium from patients with PsA compared to RA, and a perivascular distribution of 
these complexes (70). S100A12 is also strongly expressed in inflamed synovial tissue 
in both RA and PsA (96), and the expression pattern of this protein as well is 
perivascular in both diseases (98). Increased expression of RAGE has been 
demonstrated on the surface of synovial tissue macrophages in RA (110). 
1.3.3 S100 proteins, RAGE and atherosclerosis 
There are associations between arthritis and atherosclerosis in sense of comorbidity 
and in similarities at a pathophysiologic level. Atherosclerosis is a complex 
inflammatory prosess following an endothelial dysfunction initiated by mechanical, 
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biochemical, inflammatory or genetic alteration (108). The finding of S100A8/A9 in 
atherosclerotic intima while not in unaffected arteries, has led to the proposal that 
S100A8 and S100A9 may influence Ca2+-dependent processes of atherosclerosis 
(86). S100A8/A9 up-regulates thrombospondin 1, which promotes platelet 
aggregation (111). S100A8/A9 as carrier of AA to endothelial cells has already been 
mentioned (106,107). 
S100A12 exerts effects through interaction with RAGE, of which activation has been 
implicated in pathological processes such as diabetic macrovascular disease, 
amyloidosis, tumour biology and inflammatory response, as reviewed by Schmidt et 
al (112). The multiligand receptor RAGE is also stimulated by Advanced Glycation 
End products (AGE), the products of nonenzymatic glycation and oxidation of 
proteins that accumulate in diabetes mellitus and aging (113). A Norwegian review of 
this field has been published by Omsland et al (114). In diabetes mellitus RAGE 
stimulation by AGE seems to be implicated in development of accelerated 
atherosclerosis and CVD (115). Elevated S100A12 in serum has also been reported in 
patients with diabetes (116). A corresponding link between RA and accelerated 
atherosclerosis with S100A12 or other RAGE ligands has been proposed (35). This 
would make blocking of RAGE an even more interesting treatment modality for 
patients with RA or other inflammatory diseases (117). 
1.4 Polyunsaturated fatty acids and inflammation 
Among important general inflammatory mediators are the eicosanoids including 
prostaglandins, prostacyclins and leukotrienes. The eicosanoids contain 20 carbon 
atoms (from the Greek eikosi, “twenty”) and are generated from polyunsaturated fatty 
acids (PUFAs) liberated from cell membrane phospholipids. Metabolism of these 
PUFAs by cyclo-oxygenase (COX) produce thromboxans, prostaglandins and 
prostacyclins, while metabolism by lipo-oxygenase (LOX) produce leukotrienes 
(figure 5) . 
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The designation polyunsaturated indicates that these fatty acids have two or more 
double bonds in the carbon chain, the position of which determines important 
function upon metabolisation. Further, the position of the first double bond counted 
from the methyl end gives basis for grouping PUFAs into subclasses such as omega-3 
(n-3) and omega-6 (n-6) (118). Generally, eicosanoids derived from the n-6 PUFA 
arachidonic acid (AA) are more potent triggers of inflammatory responses than those 
derived from the n-3 PUFAs docosahexaenoic acid (DHA), docosapentaenoic acid 
(DPA) and eicosapentaenoic acid (EPA) (119,120).  
Humans are not able to form double bonds in the n-3 position, but marine oils are 
good sources for n-3 PUFAs. Membranes of human inflammatory cells typically 
contain approximately 20% of AA, and only small amounts of DHA and EPA; 
therefore AA is the dominant substrate for eicosanoid synthesis (118,121). The 
membrane PUFA composition of human inflammatory cells is influenced by the diet, 
Figure 5. Simplified pathways for metabolisation of polyunsaturated fatty acids to 
eicosanoids. Modified from (119). 
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and intake of marine n-3 PUFAs may reduce the production of AA-derived 
eicosanoids through several mechanisms. These include decreased availability of AA, 
competition for COX and LOX and decreased expression of some of the COX and 
LOX enzymes (122). In addition, peripheral mononuclear blood cells from healthy 
volunteers taking marine n-3 PUFA supplements exhibit reduced production of IL-1, 
IL-6 and TNF-α as well as decreased lymphocyte activation (123).  Calder (120,121) 
and Stulnig (122) review further mechanisms for antiinflammatory effects of n-3 
PUFAs. There is ample evidence that dietary intake of fish oil may have beneficiary 
effects in RA, with regard both to inflammation (124,125) and CVD (126). Although 
recently questioned in a meta-analysis (127), supplementation with n-3 PUFAs is 
presumed to prevent development of CVD in the general population, as briefly 
discussed in (128).  
1.4.1 Seal oil 
Fish oil and seal oil have approximately the same total amount of n-3 PUFAs, but 
seal oil contains more DPA than fish oil. Although there is slightly less EPA and 
DHA in seal oil than in fish oil, intake of seal oil increases the serum level of EPA 
considerably more than intake of fish oil (129). The n-3 PUFAs thus seem to be more 
available from seal oil than from fish oil, possibly by being located mainly in position 
2 (the middle) of the triacylglycerol molecule in fish oil, while located almost 
exclusively in the 1 or 3 positions in seal oil (130). Both pancreatic and lipoprotein 
lipases are position 1 and 3 specific in humans (131). Short-term duodenal 
administration of seal oil to patients with IBD-related joint pain showed beneficial 
effects in two recent studies (132,133).  
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2. Aims of the study 
The overall aim of the study was to investigate the S100 proteins calprotectin and 
S100A12 as markers of disease activity or distinct clinical features in patients with 
either RA or PsA. 
The specific aims of the studies were to: 
 Estimate the prevalence of PsA in a defined population, and to characterise the 
clinical manifestations and medical treatment for PsA (Paper I). This study was 
also the basis for case finding for further studies of S100 proteins and PUFAs in 
PsA. 
 Explore effects of short-term oral supplementation with seal oil in patients with 
PsA, and to quantitate calprotectin in feces as a measure of enteric inflammation 
(Paper II). 
 Examine plasma calprotectin as a possible predictor of joint damage and 
functional disability in RA (Paper III). 
 Analyse relations between serum levels of S100 proteins and disease activity in 
RA, as well as to the prognostic factors RF, anti-CCP, ExRA and CVD (Paper 
IV).  
 Investigate serum levels of S100 proteins as markers of disease activity, distinct 
clinical features or radiological findings in patients with PsA (Paper V). 
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3. Material and methods 
3.1 Patients and study design 
Paper I: Cross-sectional study of PsA. Patients with PsA living in the county of 
Hordaland were identified from the diagnostic codes for the period 1999-2002 at the 
4 rheumatologic centers that serve the population. In addition to the Department of 
Rheumatology, HUH, these are Haugesund Rheumatism Hospital located south of 
Hordaland, and 2 private practising rheumatologists in Bergen. The hospitals used the 
International statistical classification of disease and related health problems-10 (ICD-
10) (134), and records for patients with the following codes were assessed for 
inclusion: L40.5 (arthropathic psoriasis), M07.0-3 (psoriatic arthropathies), M46.1,8-
9 (sacroiliitis/inflammatory spondyloarthropathies). The private practising 
rheumatologists identified the patients manually. Data about skin and joint 
manifestations, treatment of PsA as well as laboratory and radiographic data as 
described by radiologist were extracted from the patient records. 
Paper II: Clinical trial with seal oil in PsA. Among the above-described population, 
patients with polyarticular PsA were mailed a written inquiry to participate in the 
trial. Patients were assessed at the baseline visit, and if eligible, included and 
randomly allocated to treatment with either seal oil (n=21) or soy oil, serving as 
placebo (n=22). Ten ml of study oil was self-administered orally before meals three 
times a day for 14 days. The patients were reassessed at week 2 (end of the treatment 
period) and week 6 (4 weeks post-treatment). In addition to clinical assessment and 
blood samples at each visit, the patients delivered stool samples at week 2. 
Paper III: Longitudinal and cross-sectional study of RA. Seventy consecutive in-
patients with RA were examined in 1992 at the Department of Rheumatology, HUH 
(69). These patients were mailed an inquery to be reassessed five years later. Nine of 
the 70 enrolled patients had died during the period and two were lost for follow-up 
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because of disability. Three patients were excluded from further study because they 
were found not to have RA although they fulfilled the classification criteria for the 
diagnose at inclusion. Thus 56 out of 70 subjects were interviewed and clinically 
reassessed, blood samples were drawn, and radiograms of their hands were obtained. 
Paper IV: Cross-sectional study of RA. Data from 129 RA outpatients at the Department 
of Rheumatology, HUH, was collected and analysed. The initial 115 patients had 
been consecutively included in a previous study (135). Additional 14 patients were 
included in order to examine laboratory aspects of the recently developed ELISA 
assay for S100A12 as well (136). Patients were interviewed and clinically assessed 
and blood samples were drawn once. Patients and their records were checked for 
presence of CVD and ExRA, as described in section 3.2.2. 
Paper V: Cross-sectional study of PsA. Patients identified from paper I, who during 
the previous year had attended our clinic with one or more swollen joints or with 
axial symptoms were sent an inquiry to be studied. To further select patients with 
active disease, those treated with TNF-α blockers were excluded, as were patients 
with any infectious disease, surgical interventions or who had received intraarticular 
glucocorticoids during the previous month. Thus, 119 responders with presumably 
active PsA were interviewed and clinically assessed once, and radiograms of hands, 
feet, pelvis and the lumbar spine were obtained if not already performed within the 
previous year. 
3.1.1 Ethical and legal considerations 
Paper I. The prevalent cases were not specifically assessed as a part of the study, 
rather they were identified from the hospital codings. Data for disease manifestations 
and treatment were extracted from the records, and this sensitive information was 
handled with secrecy and with permission from the Norwegian Directorate of Health 
and Social Services (SHdir) and in accordance with the Norwegian Social Science 
Data Services (NSD). Patients were not informed that they were included in the 
study. 
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Paper II. The study was approved by the Regional Committee for Medical Research 
Ethics (REK), and data were handled in accordance with NSD. All patients gave 
informed written consent, and were allowed to withdraw from the study without 
specific reasons at any time. The trial participation may have been time consuming in 
terms of three consultations of about one hour each at our department, and may have 
interferred with daily life since the study oil was prescribed in three daily doses for 
two weeks. Blood samples were drawn at the three visits, and the patients collected 
stool sample at home at one occasion. Further, they were informed about the risk of 
some degree of gastrointestinal discomfort by ingesting the study oil. Two patients 
withdrew from the study due to such discomfort. To our knowledge, no serious side 
effects related to intake of the actual doses of soy or seal oil have been reported in the 
literature.  
Paper III. The patients were mailed a written inquery to be assessed once at our 
outpatient clinic. After clinical assessment of those who responded, blood samples 
were drawn, and patients were referred to radiographic assessment of the hands if not 
obtained within the last year. This implied a certain dose of radiation. The collection 
of data was approved in 1997 by the Norwegian Board of Health Supervision 
(Statens Helsetilsyn) and The Data Inspectorate (Datatilsynet). 
Paper IV. Patients had been included in a previous study during a regular 
consultation for RA at our outpatient clinic in 1998 (135). They gave informed, 
written consent to the inclusion. The consultations were more time consuming for the 
patients than usual because of the data collection, and extra tubes of blood were 
drawn than at regular controls. REK and SHdir approved the use of clinical data and 
new analyses of frozen serum samples for the use in paper IV. 
Paper V. Approved by REK and in accordance with NSD, patients identified in paper 
I were mailed a written inquery to be assessed once at our outpatient clinic. In 
addition to the study consultation, blood samples were drawn once, and they were 
referred to radiographic assessment of hands, feet, spine and pelvis if not obtained 
within the last year. 
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3.2 Disease criteria and assessments 
3.2.1 PsA studies (papers I, II and V) 
Most patients with PsA in the studies had the diagnosis of psoriasis confirmed by a 
dermatologist. Palmoplantar pustulosis was regarded as a variant of psoriasis. 
Peripheral arthritis was considered present if there had ever been tender and swollen 
joints as assessed by a rheumatologist. Patients with psoriasis and peripheral arthritis 
were considered to have PsA, but RA if rheumatoid nodules were present. Presence 
of spondylarthritis was based on radiological evidence of sacroiliitis, paravertebral 
ossification or spinal syndesmophytes as assessed by a radiologist in a clinical 
setting. If the radiographic features of spondylarthritis were asymmetric or unilateral 
(40), or if polyarthritis was present as well, the patient was considered to have PsA, 
otherwise AS. Patients with crystal induced arthritis, reactive arthritis, connective 
tissue disease or osteoarthritis were excluded.  
The patients with PsA were grouped into subclasses according to accumulated 
disease pattern at their last visit in the study period: Monoarthritis, oligoarthritis, 
polyarthritis (5 or more joints affected), and spondylarthritis without peripheral 
arthritis. In addition, presence of arthritis mutilans was recorded, defined as shortened 
fingers with excessive skin folds, hypermobile joints and digits that can be elongated 
by traction (137). The numbers of tender and swollen joints were assessed by use of 
the 44 joint count according to the European League Against Rheumatism (EULAR) 
(138) added DIP joints of fingers, yielding 52 joints. Skin manifestations were 
assessed using the Psoriasis Area Severity Index (PASI) (139). The patient’s global 
assessment of the disease activity and pain intensity last week were recorded on a 
visual analogue scale (VAS), and physician’s global assessment of disease activity on 
a five-point Likert scale (138). The Modified Health Assessment Questionnaire 
(MHAQ) was used as functional disability score (140). Radiograms of hands and feet 
were assessed for erosions, osteolysis, juxta-articular new bone formation and 
ankylosis. Radiographic findings of pelvis and the spine were interpreted as described 
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above for the case definitions (141). The radiographic assessments were performed 
by radiologists in a clinical setting.  
In Paper II the patients’ intake of fish and seafood was recorded (ticked as either 
“never”, “approximately once weekly” or “twice or more per week”) as well as 
dietary supplementation of n-3 PUFAs. In addition we recorded the patients’ report of 
frequency of defecation and concistence of the stools. 
3.2.2 RA studies (papers III-IV) 
The diagnosis of RA was made according to the ACR criteria (9). Joints were 
assessed for swelling and tenderness. While we in paper III assessed 56 joints (142), 
28 joints were assessed in paper IV, (27) and we calculated the DAS28 (28). In paper 
III there was one assessor of joint swelling and tenderness at follow-up, different 
from the assessor at baseline. In paper IV there were two assessors. Patients’ and 
investigators’ global assessments of disease activity and pain last week were assessed 
by use of VAS (138). Patients were asked for the duration of morning stiffness, and 
functional disability was assessed by use of a translated version of the Health 
Assessment Questionnaire (HAQ) (143). In paper III, the obtained radiograms of 
hands and wrists as well as those obtained five years earlier were scored according to 
the Larsen method (144), by one experienced radiologist blinded for time sequence.  
Extra-articular manifestations of RA 
In paper IV patients were assessed for symptoms and clinical findings suggestive of 
any ExRA. The presence of rheumatoid nodules was based on finding of typical 
subcutaneous nodules. Secondary SS was considered present if two of three criteria 
were present: Xerostomia; keratoconjunctivitis sicca (reduced tear secretion as 
measured by Schirmer’s test < 5 mm/5 minutes or a positive Rose Bengal test); or 
positive anti-SSA or -SSB. Any previous history of scleritis or episcleritis was 
registered when documented by an ophtalmologist in the patient file. Presence of 
peripheral neuropathy not explained by other conditions was confirmed by nerve 
 32 
conduction studies. Pulmonary fibrosis was suspected if the patient had symptoms of 
dyspnoea or pulmonary auscultation revealed typical crepitations, and was confirmed 
by chest radiograph or high resolution computer tomography. Felty’s syndrome was 
defined as presence of splenomegaly and persistent neutropenia (<1.5x109). 
 
Cardiovascular disease 
The presence of CVD (paper IV) was based on the patient’s history, clinical 
evaluation and by review of the record for relevant confirmative procedures. Hence 
CVD was considered present if the patient had been diagnosed with ischaemic heart 
disease (i.e. angina pectoris or myocardial infarction) by a cardiologist, congestive 
heart failure confirmed by echocardiography, stroke confirmed by 
computertomography or intermittant claudications of the lower limbs confirmed with 
typical angiographic findings. Systemic hypertension alone was not considered CVD.  
3.3 Laboratory methods  
ESR and CRP were analysed routinely by the Laboratory for Clinical Biochemistry, 
HUH, (papers II-V) and so were the serum concentrations of cholesterols and 
homocysteine (paper II). The analyses of fatty acids in serum and treatment oils 
(paper II) were carried out at NIFES by use of gas liquid chromatography (Auto-GC) 
according to the description in (133). The Department of Microbiology and 
Immunology at HUH performed the detection of HLA-B27, RF and anti-CCP. The 
RF was analysed by Waaler’s test, and we used a cut-off titre ≥128 for a positive test 
(145). Anti-CCP was determined by ELISA (QUANTA LiteTM CCP IgG ELISA, 
INOVA Diagnostics Inc, San Diego, CA, USA) with cut-off value for a positive test 
≥20 U/ml.  
 
Stool samples from patients in paper II were analysed for calprotectin (146) using the 
Nycotest Phical ELISA kit (Nycomed, Norway), carried out at the Section for 
gastroenterology, IFI. Calprotectin concentrations were determined by ELISA in 
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plasma samples at Ullevaal University Hospital (UUH) in paper II and from frozen 
plasma samples (-70ºC ) at the Broegelmann Research Laboratory in paper III. In 
papers IV-V calprotectin was analysed in frozen serum samples at the Department of 
Microbiology and Immunology, HUH (136). At all laboratories, the ELISA test was 
based upon the same reagents and technique (146). Briefly, the calprotectin assay was 
developed from calprotectin purified from human leukocytes. Polyclonal 
immunoaffinity purified antibodies were obtained from rabbit anti-serum. These 
antibodies were conjugated with alkaline phosphatase. The IgG-fraction of rabbit 
anti-calprotectin serum was used for coating of microwell plates (MaxiSorp, Nunc, 
Denmark). Dilutions of calprotectin were used as standards. Optical densities were 
read at 405 nm after reaction with substrate. The reference interval for calprotectin in 
plasma (UUH) is 0.1-0.9 mg/l (100-900 microgram/l) and the reference 
concentrations in serum (mean ± 2 SD) 0.51-4.10 mg/l based on samples from 150 
blood donors (136). 
 
Serum samples from the patients of paper IV-V were stored at -70ºC and quantified 
for S100A12 with the recently developed ELISA test (136). The assay was based on 
recombinant S100A12 and polyclonal immunoaffinity purified antibodies obtained 
from rabbit anti-serum. Dilutions of the recombinant S100A12 were used as 
standards. The reference concentrations for S100A12 in serum are (mean ± 2SD) 
0.04-1.57 mg/l (136). 
3.4 Statistics 
The statistical analyses were performed using SPSS software (SPSS Inc., Chicago, 
IL). We used the mean and standard deviation as measures of central tendency and 
dispersion, but the median and interquartile range (IR) for data not normally 
distributed. An exception was made in paper II where we used the range as measure 
of dispersion. 
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In paper I the prevalence rates were estimated by dividing the number of identified 
cases by the population as obtained from Statistics Norway, for the chosen age 
categories. Descriptive statistics were used to analyse the clinical manifestations and 
treatment. For continous data we used the t-test or one-way analysis of variance 
(ANOVA) to test for differences between groups, for categorical variables the chi-
square test was used. The independent relationship between age, disease duration, 
CRP and type of joint affection (mono- or oligo- versus polyarthritis) was examined 
in a forward logistic regression model, yielding the parameters odds ratio (OR) and 
the 95% confidence interval (CI). 
 
In paper II changes in disease variables from baseline were tested by use of the 
Wilcoxon sign rank test, or paired samples t-test for normally distributed data. 
Differences between the two treatment groups were tested by use of the Mann-
Whitney test, or t-test for normally distributed data. A power calculation was 
performed. The number of subjects completing the study (n=40) was chosen to give 
enough power to detect a difference of 10 mm on a 100 mm VAS for joint pain or 
patient’s global assessment before and after treatment. Since we in paper II studied 
several end-point variables, p-values <0.01 were considered statistically significant. 
For the remaining papers (I, III-V) two-tailed p-values <0.05 were considered 
statistically significant.  
In cross-sectional studies (papers II-V) the Spearman rank order correlation test was 
used to correlate clinical and laboratory disease variables, yielding correlation 
coefficients r. The Mann-Whitney test was used to compare subgroups of patients. 
The OR and 95% CI for multivariate independent associations between variables 
were calculated using multiple logistic regression analyses. This yielded the OR and 
95% CI for significant associations between baseline calprotectin and subsequent 
joint destruction and disability (paper III) and between S100 proteins and 
concomitant ExRA / CVD in RA (paper IV) and radiographic joint changes in PsA 
(paper V).  
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4. Results 
4.1 Paper I  
Prevalence, disease manifestations and treatment of psoriatic arthritis in 
western Norway. 
Among adult inhabitants of Hordaland, 634 PsA patients were identified, equivalent 
to a prevalence of 1.95 per 1000 (CI 1.80-2.10). The prevalence rates were highest in 
the age group 40 to 59 years: 2.83 per 1000 men (CI 2.40-3.26) and 2.33 per 1000 
women (CI 1.93-2.73). Polyarthritis was the most frequent subclass in both genders 
(68.6%). Oligoarthritis, monoarthritis and arthritis confined to the spine or sacroiliac 
joints were seen in 22.9%, 5.8% and 2.7% of the cases, respectively. Exclusive DIP 
joint involvement was not found in any patient, and only 4 (0.6%) had arthritis 
mutilans. Mean age (50.6 years for all cases) was higher, and mean disease duration 
(10.7 years for all cases) was longer with increasing number of joints affected. Also 
the mean ESR and CRP were higher with increasing number of joints affected and 
with longer disease duration. These findings seem to reflect oligo-and polyarthritis as 
stages of disease progression rather than subclasses of PsA. 
4.2 Paper II  
Subjective improvement in patients with psoriatic arthritis after short-
term oral treatment with seal oil. A pilot study with double blind 
comparison to soy oil. 
40 patients completed the study, 20 in each treatment group. Patients in the seal oil 
group reported a significant improvement in global assessment of the disease 4 weeks 
post-treatment (p<0.01). Both groups had a tendency of improvement in the tender 
joint count, but the differences between the groups were not significant. There was a 
fall in the ratio of n-6 to n-3 fatty acids and in AA to EPA in serum after treatment 
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with seal oil (p<0.01). Supplementation of seal oil may have a symptomatic effect in 
PsA and therefore reduce the need for NSAID. Of CRP, ESR and calprotectin, the 
latter was the biomarker with highest correlation with a clinical variable (r=0.33); the 
tender joint count (p<0.05). 21 % of all patients had elevated values of calprotectin in 
feces suggestive of asymptomatic enteritis (figure 6). 
 
 
 
 
 
 
 
4.3 Paper III 
Leukocyte protein calprotectin and outcome in rheumatoid arthritis. 
Significant correlations were found cross-sectionally at follow-up between 
calprotectin concentration and other parameters of disease activity: CRP (r=0.67), 
investigator’s global assessment of disease activity (r=0.57), HAQ score and number 
of swollen joints (both r=0.48) and ESR (r=0.43). Calprotectin at baseline was not 
identified as an independent predictor for HAQ or radiographic progression in the 
multivariate analysis. 
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Figure 6. Concentration of calprotectin in stool samples from patients with PsA.  
(Figure made by Professor Arnold Berstad) 
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4.4 Paper IV 
Serum level of S100A12 is strongly associated with extra-articular 
disease manifestations in rheumatoid arthritis. 
Among the 129 patients studied, 43 (33.3%) had ExRA and 17 (13.2%) had CVD. 
Serum concentrations of S100A12 correlated with all performed measures of RA 
disease activity (r ranging from 0.22-0.51, all with p<0.01). These correlations were 
weaker than for CRP and calprotectin. The median level of S100A12 was higher in 
patients positive for RF (p<0.001) (Figure 2), anti-CCP (p<0.001) and in patients 
with ExRA (p=0.001) than in those without these features. The serum level of 
S100A12 was stronger associated to ExRA (OR 1.664, p=0.003) than was the RF 
titre (OR 1.206, p=0.009). S100A12 may thus have prognostic value in RA. 
Extremely high levels of S100A12 were mainly seen in seropositive patients (figure  
Figure 7. Box plots of the serum concentrations of calprotectin and S100A12 separated 
by presence of rheumatoid factor (n=129). The lines inside each box show the median 
values. Each box shows the 25th and the 75th percentile. The lines outside the boxes 
show the 10th and the 90th percentiles. 
Reference values: 
Calprotectin: 0.51-4.10 mg/l 
S100A12: 0.04-1.57 mg/l 
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4.5 Paper V 
S100 proteins calprotectin and S100A12 are related to radiological 
changes, rather than disease activity in psoriatic arthritis. 
Data from 119 patients with PsA were analysed. The correlations to clinical disease 
activity parameters were stronger for CRP than for ESR and calprotectin. In the 
regression analysis, calprotectin was identified as independently associated with 
peripheral radiographic features of arthritis (OR 1.33, CI 1.01-1.76). S100A12 levels 
were also elevated in those with peripheral radiographic features (p=0.036), but did 
not correlate with clinical variables of disease activity. 
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5. Discussion 
5.1 Prevalence, manifestations and treatment of PsA 
5.1.1 Methodological considerations paper I 
The county of Hordaland has natural boundaries towards surrounding regions and has 
a stable population. Only residents of the county were included, and by using unique 
personal identification numbers we also identified residents that had attended 
Haugesund Rheumatism Hospital, located south of Hordaland. These factors 
increased the sensitivity of identifying the prevalent cases. Based on a thorough 
collection of data from the patient records we excluded cases incorrectly coded as 
PsA. A calculation of the positive predictive value of this coding yielded 60.3%. By 
exploring a number of patients (n=100) coded with other arthritides, we calculated 
the negative predictive value of the coding to be 99.0%. 
Some features of the study may have effects towards an underestimation of the 
prevalence. PsA is known for a variable clinical course and may enter remission (43). 
Thus some patients may not have sought rheumatological service during the study 
period, and this may explain the lower prevalence rates that we found in the elderly 
patients. But in addition there may be a spontaneous remission of the disease in 
elderly. Cases with mild or self-limiting arthritis may also not have been identified in 
the study. Arthritis that precedes psoriatic skin lesions will not be recognized as PsA, 
and arthritis confined to the sacroiliac joints or the spine remains unrecognized unless 
radiographic features of spondylarthritis are revealed.  
Studies using the ESSG criteria will also include some patients without radiographic 
findings, while we diagnosed spondylarthritis only with radiographic manifestations 
present. Peripheral arthritis was considered to be present once a rheumatologist had 
diagnosed swollen and tender joints, thus we may have included some patients with 
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self-limiting arthritis. This may concievably have contributed to an overestimation of 
the prevalence of PsA. For a small number of the prevalent cases the diagnosis of 
psoriasis had not been confirmed by a dermatologist. Assuming that some of these 
did not have psoriasis, still the effect on the calculated prevalence rates would be 
neglishable due to the small number of such patients.  
The finding of positive RF in 4.1% of the cases is in line with studies of blood donors 
at our clinic (145), and in patients with PsA as in the CASPAR study (52), but RF 
positivity may also indicate that some patients with RA were included. The use of 
patient records gives data for both the cumulated disease course and a cross-section at 
the last visit, but as a source for radiographic data it reflects everyday practice, and 
this may have influenced the assessment of an arthritis case as either PsA, AS or 
osteoarthritis. We found PsA confined to the sacroiliac joints or the spine in only 
2.7% of the cases, and there were fewer men in this group than expected. The fact 
that relatively few patients had been radiologically assessed and a bias towards 
diagnosing men with spondylarthritis with AS instead of PsA might explain this.  
5.1.2 Prevalence and disease manifestations of PsA 
The estimated prevalence of PsA was higher than reported in some other studies. A 
Greek study (147) found a prevalence rate of 0.57 per 1000 and the Rochester 
Epidemiologic Project of Olmsted County, Minnesota USA, reported a rate at 1.01 
(47). The hitherto lack of universally agreed or validated case-definitions for PsA 
may be one probable reason for discrepancy in the literature regarding prevalence. 
Taking the methodological considerations into account, we believe that our 
prevalence rates are rather under- than overestimated, and that the true prevalence of 
PsA in our region is higher than indicated in previous studies. The study of 
inflammatory joint diseases in Finland (1) reported an incidence of PsA at 2/3 of that 
of RA, which also indicates that PsA is more common than earlier documented. 
According to both a Norwegian health interview survey (148) and a study of a 
Norwegian Lapp population (37) the overall prevalence of psoriasis was 1.4% in both 
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genders. By using the prevalence of PsA from paper I, the calculated prevalence of 
PsA among adult psoriatics is 14%. In comparison, a Swedish study of psoriatics who 
responded to a questionnaire found that 33% of patients with psoriasis had previous 
or actual peripheral arthritis and/or axial disease (149). And in a survey among 
members of the Nordic Psoriasis Patient Organisation 33.8% of the Norwegian 
members reported they had been diagnosed with PsA by a rheumatologist or 
dermatologist (38).  
With increasing number of affected joints, the mean age of the patients in paper I was 
higher and the mean disease duration longer. This indicates that patients who present 
with mono- or oligoarthritis tend to evolve into polyarthritis over time. Such a shift 
from oligo- to polyarthritis has been described earlier (150,151). The ESR and CRP 
were higher with longer disease duration and higher for patients with polyarthritis 
than for those with mono- or oligoarthritis. This may reflect a higher general disease 
activity over time as more joints are affected.  
The distribution on the different subclasses of PsA in paper I is similar to that of a 
previous study (150), were the patients had about the same disease duration (12 
years) as our patients. But this distribution of subclasses is the opposite of the 
classical description by Moll & Wright, where oligoarthritis was reported to be the 
most frequent subclass of PsA (2). Our findings of HLA-B27 must be interpreted 
with caution because of missing data, but are in accordance with previous studies that 
have demonstrated that HLA-B27 is strongly associated with axial disease, but 
weakly with peripheral arthritis (151). 
Intraarticular injections of glucocorticoids had been administered frequently to 
patients in paper I. The use of such injections in arthritis is described in a survey 
among Norwegian rheumatologists, who generally consider this a very effective 
treatment with few side effects although of limited duration (152). The wide use of 
joint injections may be seen in connection with a relatively low frequency of 
DMARD-use (40%). Some other studies have reported more frequent use of 
DMARDs, and differences may be related to different study designs (prospective 
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versus the present cross-sectional study) or be related to differences between patients 
with short and long disease duration. Few patients were treated with biological 
agents; Infliximab was introduced, and etanercept was not yet approved for treating 
patients with PsA during the study period.  
High levels of calprotectin in feces of patients without symptoms suggesting enteritis 
(paper II) indicate that several patients with PsA may have asymptomatic enteritis. 
The diversity of skin-, joint- and enteric manifestations of patients with psoriasis 
constitutes the basis for the proposal of using the term psoriatic disease rather than 
psoriasis, PsA, psoriatic enteropathy and further (153). 
5.2 Seal oil treatment in PsA 
5.2.1 Methodological considerations paper II 
Patients included in the study were homogenous in terms of clinical presentation of 
PsA by having polyarthritis. This was decided in order to overcome the complex 
outcome measure of axial disease and mono- or oligoarthritis in clinical trials. Given 
the limited expected effects of the treatment on objective manifestations, use of major 
response criteria for PsA such as the psoriatic arthritis response criteria (PsARC) 
(154) or disease activity scores (DAS) did not seem appropriate. Instead, we assessed 
several clinical relevant parameters looking for short-term responses to the 
intervention, with emphasis on detecting differences in the subjective measures.  
Considerations about joint assessment are dicussed later under paper V. The included 
patients generally had low disease activity as measured by ESR, CRP, PASI score 
and joint counts. This may have limited the potential for recording improvement by 
any treatment. Most of the patients had normal values of CRP. Interestingly, 
calprotectin levels in plasma correlated more strongly to clinical disease activity 
parameters than CRP, although generally the correlation coefficients were low; at 
0.33 and below. A major concern about this study is the short duration of treatment 
 43
given the proposed mechanisms of action. The fact that 62.5% of the patients were 
able to identify which oil they had received indicates that blinding was not complete. 
Another question is whether soy oil is a real placebo in this setting, its content of 
other PUFAs than AA, DHA and EPA implies that supplementation of soy oil may 
have some effects on the composition of eicosanoids through metabolism. 
5.2.2 Effects of omega-3 fatty acid supplementation 
Treatment with marine n-3 PUFAs has been studied in several rheumatic diseases, 
but to our knowledge this is the first study of PsA. Patients treated with seal oil 
reported a significant but modest improvement in the global assessment of disease 
(paper II). This is in line with studies of treatment effects of fish oil in RA (124,125) 
and with seal oil in patients with IBD-related joint pain (132,133). But the patients 
treated with seal oil (paper II) reported less reduction of joint pain. An explanation of 
the discrepancy between global assessment and joint pain might be that the treatment 
relieved symptoms that we did not record, like stiffness or fatigue. The energy gain 
resulting from intake of seal oil might relieve fatigue, but this may apply to soy oil as 
well.  
Among anti-inflammatory effects that can be expected from marine oils is inhibited 
synthesis of the nociceptive prostaglandin E2 by COX through reduced metabolism of 
AA by competition from EPA and DHA. But the effects of n-3 PUFA 
supplementation lacks the immediacy of the analgesic response to NSAID (155) 
because PUFAs are built into the cell membranes before being more extensively 
available as substrate for eicosanoid production (122). Long term supplementation 
with marine oils may reduce the need for NSAID (156,157), and in contrast to 
NSAIDs (158) reduce the risk for CVD (159). In addition, marine oils may have 
antiinflammatory effects by other mechanisms as inhibition of cytokine production 
by mononuclear cells (123).  
We clearly demonstrated absorption of PUFAs from the seal oil into the circulation, 
and a shift in fatty acid composition in serum toward a putative antiinflammatory 
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state. Such a shift may occur more rapidly after seal oil- than fish oil treatment 
because of the conformity between positioning of the n-3 PUFAs in the 
triacylglycerol molecules in seal oil (130) and the specificity of the human lipases 
(131). However, paper II was not designed to give evidence for this or other 
advantages of seal oil compared to fish oil. 
5.3 Calprotectin and S100A12 in RA 
5.3.1 Methodological considerations papers III-IV 
In accordance with the baseline assessment (69), we used the 56 joint count at the 
follow-up as well (paper III), although in the meantime the 28 joint count had been 
validated in RA (27). The 28 joint count was used in paper IV, and this also allowed 
the calculation of DAS28.  
In paper III most variables reflecting disease activity were higher at baseline than at 
follow-up. This may in part be due to the study group consisting of in-patients, thus 
creating a bias towards higher disease activity at inclusion with subsequent regression 
towards the mean. We studied relatively few patients (n=56) and some had long 
disease duration at baseline. This may have influenced on the assessment of 
radiographic progression since most of the erosions come early and there is a ceiling 
effect of developing erosions in established disease (160). 
Patients in paper IV seemed at inclusion (mainly in 1998) to have high disease 
activity and were less aggressively treated than today’s standards; The median 
methotrexate dose was 10 mg/week, and only 2 patients were on TNF-α blocking 
therapy. In the study of inflammatory markers, this may be an advantage since the 
bias of treatment effects is reduced. Patients were not systematically evaluated for 
CVD, rather the presence of such was based on the patient’s information, thorough 
clinical examination and necessary confirmative investigations as documented in the 
medical record. Thus, patients with clinically silent CVD were not identified.  
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All patients were thoroughly assessed for presence of ExRA with subsequent 
confirmatory investigations as outlined, but pulmonary radiograms and measurement 
of tear secretion were not systematically performed and the identification of 
pulmonary fibrosis or secondary SS may be incomplete. Whereas we included 
secondary SS and rheumatoid nodules as ExRA, the referred associations between 
severe ExRA and excess CV morbidity (31) and mortality (30) do not include these 
ExRA. Further considerations regarding common study design for papers III-V are 
discussed below.  
5.3.2 Calprotectin 
Calprotectin is comparable to CRP as a marker of disease activity in RA, and 
correlates with arthritis activity in cross-sectional studies (65,66,69). This was 
confirmed in papers III-IV. The joint damage assessed by the Larsen score is a direct 
and objective outcome measure in RA, representing a cumulative result of the disease 
independent of the current disease activity. This damage is accompanied by 
functional impairment of the patient (161,162), although assessment of this by use of 
the HAQ score may also be influenced by the disease activity (163). On this 
background radiographic progression and HAQ are relevant outcome variables when 
studying prognostic factors.  
In paper III baseline calprotectin was not identified as predictive for damage or 
disability. However, the methodologic limitations discussed above may have biased 
this result. A subsequent cross-sectional study of 145 RA patients revealed consistent 
associations between calprotectin and two measures of joint destruction; The 
modified Sharp score and the RA articular damage score (164). In that study, the 
multivariate regression analyses identified calprotectin and RF as significant 
covariates for both measures of joint destruction, whereas CRP and ESR were not. 
This study has a similiar design to paper III, but has some advantages such as higher 
number of patients, shorter and equal disease duration and two separate endpoints for 
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joint damage. Accordingly, there seem to be an association between calprotectin 
levels and joint destruction in RA although we did not demonstrate this in paper III.  
5.3.3 S100A12 
To our knowledge, paper IV is the largest study of S100A12 and disease activity in 
RA, and we show that serum levels of S100A12 reflect the disease activity, which 
was previously indicated in a study of different types of arthritis, including nine 
patients with RA (96). Levels of S100A12 in serum correlated with all assessed 
measures of disease activity, although the correlations favoured CRP and calprotectin 
compared to S100A12 as biomarkers of disease activity (paper IV ).  
The serum levels of S100A12 were more frequently elevated than calprotectin, and 
significantly higher in patients with RF, anti-CCP or ExRA compared to those 
without such features. Whereas the association between RF and ExRA is well known 
(165,166), our results indicate an even stronger association between S100A12 and the 
presence of ExRA. Conflicting results exist for the association between anti-CCP and 
ExRA (165,166), and in the logistic regression analysis we did not identify anti-CCP 
as an independent factor for presence of ExRA. Our findings indicate that S100A12 
may be of prognostic relevance since RF, anti-CCP and ExRA are recognised as risk 
factors for both joint destruction (167,168) and CVD (166) in RA. However, in paper 
IV neither S100A12, RF titre nor the anti-CCP levels were significantly higher in 
patients with CVD. The elevated concentrations of S100A12 in patients with anti-
CCP, high titres of RF or ExRA suggests a pathophysiologic role of S100A12 in a 
subset of RA patients with severe disease. 
In paper IV we did not investigate the relation between levels of S100 proteins and 
extent of joint damage. However, in a study performed to identify a panel of 
candidate protein biomarkers of RA that could predict erosive disease, only CRP, 
S100A8, S100A9 and S100A12 were recognised as such (97). This may indicate a 
role of S100A12 as well in the joint destruction seen in RA.  
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5.4 Calprotectin and S100A12 in PsA 
5.4.1 Methodological considerations paper V 
The method of including patients implies an expected selection of active joint 
disease. Firstly, based on the patient population in paper I, we sent the inquery to 
those who had attended our clinic the preceding year with actual disease 
manifestations, excluding those on TNF-α blocking therapy. Secondly, one would 
expect more patients with complaints from PsA to respond to the inquery compared 
to patients with milder symptoms. But still the median values of all assessed 
biomarkers were within their reference values, and the low disease activity may lead 
to an underestimation of the associations between any biomarker and disease 
parameter. The patient characteristics regarding age, disease parameters, gender and 
RF positivity were comparable to those of the CASPAR study (52).  
There may be some reasons why the patients in paper V still have low inflammatory 
activity. Our attempt to select active disease may have failed, and if so the patients 
have characteristics of a community-based rather than a hospital-based population. 
The method of recruiting patients to the study prevented inclusion of patients with 
disease duration of less than one year. If PsA generally is more active in early stages, 
we would thereby miss some with active disease. But this is contradicted by the fact 
that we included a larger proportion of patients with polyarthritis than with mono- or 
oligoarthritis compared to the patient population in paper I. According to results from 
paper I this implies higher expected values of inflammatory biomarkers. 
In the clinical assessment of peripheral arthritis of PsA we used the EULAR 44 joint 
count (138) added the DIP joints of hands, yielding 52 joints. A reduced joint count 
of 28 joints is used in RA trials (27), but is not validated in PsA. DIP joints and feet 
should also be assessed since these joints are frequently affected in PsA, as 
demonstrated in paper I: 36% of the cases had affection of DIP joints and 52% of 
joints of the toes.  
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The assessment of spinal affection in PsA is complex. Few patients have exclusively 
spondylarthritis, but this may be revealed in up to 40% of all PsA patients if assessed 
(39). The spondylitis of PsA may be segmental and less severe than that of AS, and it 
is not clear whether clinical measures of spinal involvement developed for AS are 
sensitive or accurate for use in PsA (169). Among clinical tests for axial involvement, 
the finger-to-floor distance and occiput-wall distance (169) were measured in paper 
V. But whether pathological findings were due to spondylarthritis or degenerative 
spinal disease turned out to be difficult to distinguish, and the results were not 
presented in paper V.  
Also in imaging, axial affection in PsA may be difficult to distinguish from 
degenerative disease (40), and this applies to the radiographic assessment of arthritis 
in hands and feet as well (39). All radiographic data in paper V were obtained from 
description by a radiologist in a clinical setting. 
5.4.2 Clinical correlations 
Acute phase reactants are generally less reliable markers of disease activity in PsA 
than in RA (53). Results from paper V does not give evidence that calprotectin is a 
better marker of disease activity than ESR or CRP since we found low correlations to 
clinical disease variables, although highly significant to the swollen joint count 
(r=0.26). A previous study of a small number of patients with PsA (n=22), RA (n=11) 
and SpA (n=15), found significant correlations between serum calprotectin and ESR 
and CRP, but weaker with clinical disease activity variables (70).  
In paper V we found no correlations between S100A12 and clinical disease activity 
parameters. This is opposed to a report of significant correlation between serum 
S100A12 and the Ritchie articular index (r=0.36) in a small number of patients with 
PsA (n=18), as well as responsiveness to treatment with methotrexate (96). Taken into 
account the low disease activity of our patients, there still is a possibility that 
S100A12 reflects disease activity if higher inflammatory activity since the low 
disease activity may have lead to an underestimation of the associations between any 
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biomarker and disease parameter. Perhaps more interesting is the association between 
calprotectin, S100A12 and radiological changes (paper V), which may indicate a 
prognostic implication of these proteins in PsA. In the regression analysis, we 
identified the level of calprotectin as an independently associated factor for the 
presence of radiographic features of arthritis in hands or feet. An analogous 
association between calprotectin and radiographic score was demonstrated in RA 
(cross-sectional part of paper III). Also the serum level of S100A12 was a better 
indicator for radiographic changes of hands and feet than ESR and CRP in paper V.  
5.5 General discussion S100 proteins in RA and PsA 
5.5.1 Protein structure and measurement 
S100A8 and S100A9 show almost identical expression pattern in human and murine 
systems, while mice do not have genes for S100A12 (82). S100A8 and S100A9 may 
compensate for this lack, and results from other species may therefore be of limited 
use for processes in humans as discussed by Foell et al (170). Further, the structural 
homology of S100 proteins make the generation of specific antibodies difficult as 
cross-reactivity may exist. These facts may limit the generability of results from 
different studies.  
The concentrations of Ca2+ and other ions influence the three-dimensional structure 
and complex formation of S100A8, S100A9 and S100A12 and hence their binding 
affinities for signal transduction (24,90). Differences in the milieu of test situations 
may influence on the results and limit the comparison from various studies. Different 
laboratories performed the quantification of calprotectin in plasma samples (papers 
II-III) and serum samples (papers IV-V), but in all cases with the ELISA test 
developed in Oslo (146). Other research groups have measured the S100A8/A9 
complex, and the group with Foell, Roth and colleagues has discussed the possibility 
of pitfalls in detection of S100 proteins in patient samples related to complex 
formation in vivo and in vitro (171). Paper IV shows that calprotectin not only in 
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plasma, but also in serum may be a useful biomarker for disease activity in RA. Due 
to laboratory influences of EDTA and heparin, the analysis of S100A12 from serum 
samples is recommended (136). Our assay for S100A12 has not been tested against 
any international standard or the research groups referred to (95,96,98), therefore 
comparisons of concentrations may not be appropriate.  
The laboratory sub-study of paper IV, which is related to the development of 
S100A12 assay (136), showed that concentrations of calprotectin and S100A12 were 
unaffected by time from drawing to separation of serum or plasma (only calprotectin 
examined for EDTA plasma). Determination of S100 proteins were performed in 
samples stored in freezer (-70ºC) varying from a few months up to eight years. As 
described in (136), the concentration of S100A12 in serum was not significantly 
changed by 10 freeze/thaw cycles and was stable for at least 6 months at –20ºC 
although individual variations in stability were observed.  
5.5.2 Considerations, study design papers III-V 
Papers III-V describe associations between S100 proteins and joint destruction, 
disability, CVD and ExRA. It might be questioned whether a single analysis of 
calprotectin may predict some clinical outcome, but for other inflammatory markers 
as CRP and ESR this has been documented regarding radiographic outcome in RA 
(15,162,172). The chosen cross-sectional approach presupposes that a single 
measurement of a biomarker to some extent reflects the previous period from 
diagnosis until the actual assessment. Such a relationship has been shown for CRP 
and joint destruction in RA (13), but our study design does not allow conclusions 
about the longitudinal value of S100 proteins.  
Treatment with prednisolone, DMARDs and TNF-α blockers may significantly 
suppress the current inflammation and illustrates the methodological problem in 
studying associations between inflammatory biomarkers at one point of time and the 
accumulated joint damage or CVD. Especially in patients who recently have started 
treatment with TNF-α blockers, inflammatory biomarkers presumably do not mirror a 
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preceding disease period. For future research it would be of interest to conduct 
prospective studies of cohorts with serial assessment with endpoints such as joint 
damage, ExRA, CVD and mortality. A major problem in logitudinal prospective 
studies however, is the necessary assumption that medical treatment does not bias the 
disease outcomes. 
5.5.3 Comparison of RA and PsA with respect to S100 protein 
expression 
Peripheral blood 
A striking finding from papers IV-V was that levels of S100 proteins were less 
elevated in PsA than in patients with RA, similary to CRP and ESR (table 1). 
 
Diagnosis Paper 
ESR 
mm/h 
CRP 
mg/l 
Calprotectin 
mg/l 
S100A12 
mg/l 
Reference interval   <5 0.51-4.10 0.04-1.57 
RA 
N=129 
IV 
26  
(15-50) 
12 
(5-34) 
3.77  
(1.98-6.77) 
2.90  
(1.06-5.92) 
PsA 
N=119 
V 
13 
(6-24) 
4 
(1-8) 
2.04  
(1.25-3.04) 
0.43  
(0.22-0.78) 
 
 
 
 
Higher levels of both calprotectin (69) and S100A12 (95,96) in RA than in PsA have 
already been described. However, a comparison between RA and PsA may not be 
appropriate since the disease activity is not comparable or adjusted for. The high 
Table 1. Levels of calprotectin and S100A12 in RA (paper IV) and PsA (paper V). 
Values are presented as median (interquartile range). 
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median DAS28 in paper IV reflects the impression that our RA patients in general 
had high disease activity. Although we intended to select PsA patients with high 
disease activity in paper V, the disease activity was low as reflected by median ESR, 
CRP, calprotectin and S100A12 levels within reference values (table 1). The general 
impression that inflammatory biomarkers in peripheral blood are less elevated in PsA 
than in RA is described earlier although little understood (53).  
In PsA, the ESR and CRP are not reliably elevated even with active inflammation, 
and this may apply to S100 proteins in peripheral blood as well. Whereas serum 
levels of S100 proteins and especially of S100A12 are higher in RA than in PsA, 
there are indications that the synovial expression of calprotectin is higher in PsA than 
in RA (70).  
In both diseases S100 proteins in serum have been proposed to represent overflow 
from the local inflammation in the joints (99). The striking difference in serum levels 
of S100 proteins in RA and PsA supports the view of RA as a more systemic 
inflammatory disease than PsA, with a more activated endothelium facilitating the 
release of calprotectin and S100A12 from leukocytes. Alternatively, there may be 
differences in some “overflow mechanisms” between RA and PsA in the case of 
synovium being the source of serum levels of S100 proteins. The fact that serum 
levels of S100A12 were more elevated than calprotectin in our RA patients supports 
that the origin of these proteins is active release from circulating leukocytes rather 
than from synovial leukocyte degradation, since cytosolic concentrations of 
calprotectin is considerably higher than of S100A12. 
At the level of gene expression a previous microarray study of peripheral blood cells 
from patients with PsA identified the genes for S100A8 and S100A12 as upregulated. 
Together with other genes, they constituted a unique pattern differentiating PsA from 
RA and from healthy controls (173), with no clear distinction between RF positive 
and RF negative RA patients (174). 
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Feces 
In paper II we demonstrated that more than 20% of the patients with PsA but without 
clinical inflammatory bowel disease had increased levels of calprotectin in stool 
samples. There is large evidence that patients with PsA may have inflammatory 
changes of the enteric mucosa (42). To our knowledge this has not been studied in 
terms of fecal calprotectin secretion, neither has it been decribed for patients with RA 
per se. In a study of rheumatic patients on NSAID therapy, of whom the majority had 
RA, fecal calprotectin secretion was elevated (175). The authors state that there is 
similar elevation of fecal calprotectin in volunteers and in their patients taking 
NSAIDs, inferring that the treatment with NSAID and not the underlying rheumatic 
disease is responsible for the intestinal inflammation seen during NSAID treatment. 
The same authors are aware that this may not apply to patients with 
spodyndyloarthropathies. This study raises the question whether our finding of 
elevated calprotectin in feces (paper II) may be caused by NSAID use or psoriatic 
enteropathy. 
Synovium 
From previous studies it seems to be differences between PsA and RA regarding the 
synovial expression of S100 proteins. Immunohistological studies have described 
higher expression of calprotectin in synovium from patients with PsA compared to 
RA (70), and the synovial expression of calprotectin in PsA was demonstrated 
particularly in perivascular areas of the synovial sublining layer. According to studies 
of S100A12, the expression pattern of this protein as well is perivascular both in RA 
(94,98) and in PsA (98). Consequently, the authors point to a possible role for 
S100A12 in the angiogenesis and altered function of microvascular endothelium that 
has been reported in the synovitis of PsA (56).  
Taken together, our demonstrated associations between S100A12 and radiographic 
features (paper V), and the previously described synovial perivascular expression 
indicate that S100A12 to some extent is involved in, or serve as markers of the joint 
 54 
destruction in PsA. This may indicate a potential role of these proteins not only as 
biomarkers, but also as targets for therapy. 
5.5.4 S100A12 and vasculitis / atherosclerosis 
S100A12 has been suspected as a triggering factor for vasculitis in Kawasaki disease 
through stimulation of RAGE (176). More recently, increased serum levels of 
S100A12 have been demonstrated in patients with MPO-ANCA associated 
glomerulonephritis (177), and levels correlated with various disease activity 
variables. The authors suggest both a pathogenic role of S100A12 and the use as an 
additional helpful marker in the handling of patients with this disease. In a study of 
diabetics, high plasma level of S100A12 was strongly associated with increased risk 
of CVD (178). Hence, some degree of vasculitis and a role of RAGE activation, 
presumably by S100A12, is proposed to be a common pathologic feature of 
Kawasaki vasculitis (176), glomerulonephritis (177), diabethic angiopathy 
(116,178,179) and atherosclerosis in RA (35).  
In PsA,  the evidence for systemic inflammation is weaker and it is an open question 
whether there may exist a link between S100A12 and the reported increase in 
mortality (46) and risk of CVD (48).  
Therapeutic effects of RAGE antagonism have been studied in experimental models 
and reviewed by Bierhaus et al (117). Blockade of RAGE in collagen-induced 
arthritis suppressed inflammation (89), and delayed graft rejection in a murine cardiac 
transplantation model (180). Hopefully promising experimental results may be 
translated into treatment of inflammatory conditions in human disease. 
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6. Conclusions 
We found a higher prevalence rate of PsA in Hordaland than previously reported 
from other populations. Polyarthritis was the most frequent subclass, and the 
demographic data support the presence of a shift from mono- and oligoarthritis to 
polyarthritis and increased inflammatory activity with increasing duration of the 
disease. High levels of calprotectin in stool samples from a subset of these patients 
indicate asymptomatic enteritis. 
Previous studies give evidence for recommending dietary supplementation of fish oil 
to patients with arthritis. The double-blind randomised trial with supplementation of 
seal oil to patients with PsA was followed by a shift in the fatty acid composition in 
serum towards a putative antiinflammatory profile and a general improvement as 
reported by the patients. The study does not give evidence that seal oil is different 
than fish oil in respect of beneficial effects.  
Both calprotectin and S100A12 in serum behave as biomarkers of disease activity in 
RA. Calprotectin did not behave as a predictor of joint damage or functional 
impairment in our study of RA, but methodological issues may have biased this. 
S100A12 may be of prognostic relevance since high serum levels were found in 
patients with the unfavourable prognostic features ExRA, RF and anti-CCP. 
Extremely high values of S100A12 were detected in some patients with 
characteristics of severe disease. In some of these patients, new conformational states 
of S100A12 were detected. Further description of this will be published later. 
Patients with PsA had lower serum levels of calprotectin and S100A12 compared to 
RA patients, and these proteins did not perform better than traditional biomarkers of 
disease activity. Both calprotectin and S100A12 were associated with radiographic 
features of peripheral arthritis, and may thus have prognostic value in PsA. Our 
findings support the concept of PsA as a less systemic inflammatory disease than RA. 
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7. Future perspectives 
There is large evidence that dietary supplementation of fish oil has beneficial effects 
on arthritis and cardiovascular disease. To what extent this is applicable for other 
disease entities than RA and for other dietary sources of fatty acids should be further 
investigated in studies of longer duration and more participants. A major 
methodological problem in studying factors of minor but important effects is to 
control for other treatments or influences. 
The data presented for S100 proteins give reason to plan new studies of the 
prognostic implications of calprotectin and S100A12 in RA, PsA and other 
inflammatory rheumatic diseases. Larger prospective studies are warranted with early 
inclusion of patients into serial assessments of multiple endpoints such as joint 
damage, extra-articular manifestations, CVD and mortality.  
Future studies of S100A12 and RAGE may add knowledge to the pathogenesis both 
of the articular, extra-articular and CV aspects of RA, and may further identify 
potential targets for therapy. 
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Errata 
1. Paper II, table 3: The correct designation of calprotectin concentrations is 
mikrogram/l (not mg/l). 
2. After submission of the dissertation, the reference number 164 has been corrected 
to refer to the published article instead of the conference abstract. 
3. After submission of the dissertation, Paper I has been published with the 
following modifications: 
 The title has been added the description: ”....with low disease activity”. 
 ”Radiological (features)” has been changed to ”radiographic” througout the 
text. 
 Some linguistic corrections have been made by the publisher. 
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Prevalence, Disease Manifestations, and Treatment of
Psoriatic Arthritis in Western Norway
TOR MAGNE MADLAND, ELLEN M. APALSET, ARILD E. JOHANNESSEN, BERTHE ROSSEBÖ, 
and JOHAN G. BRUN
ABSTRACT. Objective. To estimate the prevalence of psoriatic arthritis (PsA) in a geographically defined popu-
lation, and to characterize the clinical manifestations and medical treatment for PsA.
Methods. Prevalent cases were identified for the years 1999-2002 at the rheumatology centers for
the population of 442,000 inhabitants. Clinical data were extracted from patient records. Cases with
psoriasis and peripheral arthritis and/or radiographic evidence of spondyloarthritis were considered
to have PsA, those with other arthritides were excluded.
Results. In total, 634 patients with PsA were identified from the adult population, equivalent to a
prevalence of 1.95 per 1000 (1.80–2.10). There were no significant sex differences in rates; for both
sexes the prevalence was highest in the age group 40 to 59 years. Polyarthritis was the most frequent
subclass (68.6%). Oligoarthritis, monoarthritis, and arthritis confined to the spine or sacroiliac joints
were seen in 22.9%, 5.8%, and 2.7% of cases, respectively. Mean age was higher (50.6 yrs for all
cases), and mean disease duration was longer (10.7 yrs) with increasing number of joints affected.
The mean erythrocyte sedimentation rate and C-reactive protein were higher with increasing num-
ber of joints affected and disease duration. Intraarticular injection of glucocorticoids had been
administered to 40.0% of the patients during the last year. Disease modifying antirheumatic drugs
were used by 40.0%, with oral methotrexate being the most frequently used.
Conclusion. The estimated prevalence of PsA was 1.95 per 1000 adult inhabitants, which is higher
than previously reported. The demographic data support the presence of a shift from mono- and
oligoarthritis to polyarthritis and increased inflammatory activity with increasing disease duration.
Methotrexate and intraarticular glucocorticoids were frequently used treatments. (J Rheumatol
2005;32:1918–22)
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Psoriatic arthritis (PsA) is an inflammatory joint disease
associated with psoriasis. In addition to coincidence of pso-
riasis and arthritis, PsA is characterized by various clinical
features, i.e., involvement of distal interphalangeal (DIP)
joints, asymmetry, spondyloarthritis (SpA), dactylitis, and
enthesitis1. The variability in clinical presentation led to the
description by Moll and Wright2 of 5 clinical subclasses: (1)
Arthritis with predominantly distal interphalangeal (DIP)
joint involvement; (2) arthritis mutilans; (3) symmetric
polyarthritis — indistinguishable from rheumatoid arthritis
(RA); (4) asymmetric oligoarthritis; and (5) predominantly
SpA. The term “psoriatic arthritis sine psoriasis” is some-
times used in cases with inflammatory joint disease with
clinical characteristics of PsA but without skin lesions3.
However, at an individual basis it may be difficult to dis-
tinguish PsA from other inflammatory joint diseases in a
patient with psoriasis, i.e., RA, ankylosing spondylitis (AS),
and enteropathic arthritis. This distinction is based on clini-
cal, serological, and radiographic features1. The absence of
a validated case definition of PsA represents one of the dif-
ficulties in comparing the prevalence of the disease in dif-
ferent studies. Previous studies have reported prevalences of
PsA at about 1 per 10004. Apart from a small study of a Lapp
population in Norway5 and a health interview survey of
patients with psoriasis6, to our knowledge epidemiologic
studies of PsA have not been performed in Norway. A recent
study from Finland7 estimated the annual incidence of
inflammatory joint diseases, and found PsA to be the most
frequent presentation of arthritis after RA.
Our aim was to estimate the prevalence of PsA in the
population of the county of Hordaland in Western Norway.
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Further, we wished to characterize the clinical manifesta-
tions of the disease and describe the medical treatment
patients were receiving.
MATERIALS AND METHODS
According to Statistics Norway the county of Hordaland had 441,660
inhabitants at January 1, 2003 (9.7% of the Norwegian population), among
whom 321,454 were age 20 years or older. Fifty-four percent lived in
Bergen, which is the regional center. In order to include a major percentage
of the prevalent cases, patients with PsA were identified from the diagnos-
tic codes for the period 1999-2002 at the 4 rheumatology centers that serve
the population. These are the Department of Rheumatology of the
University Hospital in Bergen, Haugesund Rheumatism Hospital (located
south of the county), and 2 private rheumatologists in Bergen. The hospi-
tals used the International Statistical Classification of Disease and Related
Health Problems-10 (ICD-10)8, and records for patients with the following
codes were assessed for inclusion: L40.5 (Arthropathic psoriasis), M07.0-
3 (Psoriatic arthropathies), and M46.1,8-9 (Sacroiliitis/inflammatory
spondylopathies). The private rheumatologists identified the patients indi-
vidually. Data about skin and joint manifestations and treatment of PsA as
well as laboratory and radiographic data as described by a radiologist were
extracted from the patient records. Radiographs of hands, feet, sacroiliac
(SI) joints, and thoracolumbar spine obtained during the last 3 years were
considered. Laboratory data included erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP, normal value < 10 mg/l), HLA-B27 anti-
gen, antinuclear antibodies (ANA), and Waaler’s test for rheumatoid factor
(RF). The cutoff value for a positive RF and ANA was titer of 128 or
ELISA 1.65 for ANA. The most recently obtained values for ESR and CRP
were considered.
Case definition. All patients seen at a department of rheumatology (n =
540) and the majority of patients seen only by a private rheumatologist (n
= 94) had the diagnosis of psoriasis confirmed by a dermatologist.
Palmoplantar pustulosis was regarded as a variant of psoriasis. Peripheral
arthritis was considered present if there had ever been tender and swollen
joints assessed by a rheumatologist. Patients with psoriasis and peripheral
arthritis were considered to have PsA, but RA if rheumatoid nodules were
present. Presence of SpA was based on radiological evidence of sacroiliitis,
paravertebral ossification, or syndesmophytes in the spine as assessed by a
radiologist in a clinical setting. If the radiographic features of SpA were
asymmetric or unilateral9, or if polyarthritis was present as well, the patient
was considered to have PsA, or otherwise AS. Patients with crystal induced
arthritis, reactive arthritis, connective tissue disease, or osteoarthritis (OA)
were excluded. The patients with PsA were grouped into subclasses accord-
ing to accumulated disease pattern at their last visit in the study period: that
is, monoarthritis, oligoarthritis (2 to 4 joints affected), polyarthritis (≥ 5
joints affected), and SpA without peripheral arthritis. In addition, presence
of arthritis mutilans was recorded, defined as shortened fingers with exces-
sive skin folds, hypermobile joints, and digits that could be elongated by
traction10.
Statistical analyses. Statistical analyses were performed using SPSS 9.0.0
software (SPSS Inc., Chicago, IL, USA). Prevalence rates were estimated
by dividing the number of prevalent cases by the population as obtained
from Statistics Norway for January 1, 2003. We calculated 95% confidence
intervals (CI) for prevalence rates with binomial distribution. Descriptive
statistics were used to analyze the clinical manifestations and treatment. We
used parametric tests with a 2-sided significance level of 0.05. For conti-
nous data we used t test/one-way analysis of variance (ANOVA) to test for
differences between groups; for categorical variables the chi-square test
was used. The mean and standard deviation were used as estimates of cen-
tral tendency and dispersion. The independent relationship between age,
disease duration, CRP, and type of joint affected (mono- or oligo- vs poly-
arthritis) was examined in a forward logistic regression model, yielding the
parameter odds ratio (OR) and the 95% CI.
RESULTS
Prevalence and demographics. We identified 634 adults
with PsA living in Hordaland; 53% were male. The estimat-
ed prevalence was 1.95 per 1000 adult inhabitants (95% CI
1.80-2.10). Age group and sex-specific prevalences are pre-
sented in Table 1. There were no significant differences in
rates between men and women: for both sexes the preva-
lence rate was highest in the age group 40 to 59 years.
Prevalence in the city of Bergen was comparable to that of
the surrounding rural regions. Demographic data for
patients are shown in Table 2. Mean age at last visit was
50.6 years (SD 14.9), and was higher with increasing num-
ber of joints affected (p < 0.05). Similarly, the mean disease
duration, 10.7 years (SD 8.8) for all patients, was longer
with increasing number of joints affected. There was no sig-
nificant sex difference between the subclasses.
Clinical manifestations. Palmoplantar pustulosis was the
dominating skin manifestation in 6.2% of patients; the
remainder had plaque psoriasis. Polyarthritis was the most
frequent subclass (Table 2), documented in 68.6% of the
patients. Oligoarthritis had been found in 22.9% of patients,
and monoarthritis in 5.8%. Exclusive DIP joint involvement
was not found in any patient, and only 4 (0.6%) had arthri-
tis mutilans. The type of joints ever affected by arthritis is
shown in Table 3. Proximal interphalangeal joints, knees,
metacarpophalangeals, or metatarsophalangeal joints were
each involved in more than half of the cases, and dactylitis
had been present in 11.7%. Radiographic assessment of SI
joints had been performed in 39.4% of cases, and evidence
of SpA was present in 33.6% of these. SpA without periph-
eral arthritis was seen in 2.7% of all cases. Because of few
patients in this group, only cases with peripheral arthritis
were considered in the statistical comparison of disease
manifestations and treatment (Table 4). When considering
the 2 main groups of peripheral arthritis (mono/oligoarthri-
tis and polyarthritis) as dependent variables, we identified
the following parameters independently associated with
type of joint involvement: age (OR 1.03, 95% CI
1.01–1.04), disease duration (OR 1.06, 95% CI 1.03–1.09),
and CRP (OR 1.03, 95% CI 1.01–1.05).
Laboratory variables and radiographic features. Positive
RF was found in 4.1% of all cases, and ANA in 4.1%. HLA-
B27 was present in 27.3% of the patients with peripheral
arthritis who had been examined for this (Table 4), but in
41.7% of those with PsA confined to SI joints or spine (p <
Table 1. Prevalence of psoriatic arthritis (per 1000). Total prevalence: 1.95
per 1000 (95% CI 1.80–2.10).
Age, yrs Men (95% CI) Women (95% CI)
20–39 1.47 (1.17–1.76) 0.98 (0.73–1.23)
40–59 2.83 (2.40–3.26) 2.33 (1.93–2.73)
≥ 60 2.09 (1.61–2.57) 2.24 (1.81–2.67)
Total 2.11 (1.88–2.34) 1.80 (1.59–2.0)
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0.05). The mean ESR and CRP were higher in patients with
polyarthritis than in those with mono- or oligoarthritis (p <
0.05). Radiographic signs of arthritis in hands or feet had
been described in 55.6% of the patients assessed for this,
and 45.2% of these had features typically seen in PsA, such
as DIP joint erosions, joint osteolysis, and juxtaarticular
bone formation. Of all cases with sacroiliitis, 34.0% had
unilateral or asymmetric changes.
Treatment of PsA. Within the year prior to the last rheuma-
tological consultation, 40.0% of the patients with peripheral
arthritis had received one or more intraarticular steroid
injections (Table 4). This treatment was equally frequent in
the polyarthritis and mono/oligoarthritis subgoups, as was
the use of nonsteroidal antiinflammatory drugs (NSAID). At
the last visit in the study period, 77.3% of these patients
used some NSAID, of which 32% were cyclooxygenase-2
selective. Disease modifying antirheumatic drugs
(DMARD) were used by 40.0% of those with peripheral
arthritis, and oral prednisolone in daily doses between 2.5
and 10 mg was used by 7.9%, mainly patients with pol-
yarthritis. Methotrexate (MTX), alone or in combinations,
was used by 66.1% and 4.4% of the DMARD users, respec-
tively. Sulfasalazine constituted 13.3%, leflunomide 5.2%,
and hydroxychloroquine 4.8% of the DMARD used, while
gold, cyclosporine, and azathioprine constituted less than
3.5% each. Biological agents were used by 1.7% of all
patients (infliximab 7, etanercept 3, and anakinra 1).
DISCUSSION
The estimated prevalence of PsA was 1.95 per 1000 in the
adult population. In comparison, the Rochester Epidemio-
logic Project of Olmsted County, Minnesota, USA, reported
a prevalence rate at 1.0111. A study from Greece12 found a
prevalence rate at 0.57, but they used the Preliminary
European Spondylarthropathy Study Group criteria13 for
Table 2. Demographic data and subclassification of 634 patients with PsA.
Subclasses
Monoarthritis Oligoarthritis Polyarthritis Spondyloarthritis p Total
Exclusively
No. of patients (%) 37 (5.8) 145 (22.9) 435 (68.6) 17 (2.7) 634 (100)
Mean age, yrs (SD) 39.8 (10.3) 47.4 (15.3) 52.7 (14.6) 49.5 (13.3) < 0.05* 50.6 (14.9)
Mean disease duration, yrs (SD) 4.8 (4.5) 8.4 (8.1) 11.8 (8.9) 11.1 (10.4) < 0.05** 10.7 (8.8)
Male (%) 15 (40.5) 80 (55.2) 237 (54.5) 4 (23.5) *** 336 (53.0)
* p < 0.05 for differences between all groups of peripheral arthritis (ANOVA). ** p < 0.05 for differences mono- vs polyarthritis and oligo- vs polyarthritis.
No significant difference for mono vs oligoarthritis (ANOVA). *** No significant difference between the subgroups of peripheral arthritis. p < 0.05 for dif-
ference between peripheral arthritis and spondyloarthritis (chi-square test).
Table 3. Joints affected by arthritis in 634 patients with PsA.
No. of Patients (%)
PIP 348 (54.9)
Knees 346 (54.6)
MCP 332 (52.4)
MTP 332 (52.4)
Wrists 279 (44.0)
DIP 228 (36.0)
Ankles 188 (29.7)
Elbows 130 (20.5)
SI joints* 84 (33.6)
Shoulders 80 (12.9)
Hips 38 (6.0)
* Assessed in 39.4% of the cases. PIP: proximal interphalangeal, MCP:
metacarpophalangeal, MTP: metatarsophalangeal, DIP: distal interpha-
langeal, SI: sacroiliac.
Table 4. Laboratory/radiographic data and treatment for the PsA patients with peripheral arthritis.
Mono/Oligoarthritis, Polyarthritis, p Total,
n = 182 n = 435 n = 617
Mean ESR, mm/h (SD) 16.0 (14.8) 22.7 (17.6) < 0.05 20.7 (17.1)
Mean CRP, mg/l (SD) 8.8 (15.0) 13.5 (17.9) < 0.05 12.1 (17.3)
Positive HLA-B27†, n (%) 28 (28.0) 60 (27.0) * 88 (27.3)
Radiographic arthritis, hands or feet††, n (%) 17 (26.2) 208 (61.2) * 225 (55.6)
Intraarticular steroid injection last year, n (%) 74 (40.7) 173 (39.8) 0.84 247 (40.0)
NSAID use currently, n (%) 134 (73.6) 343 (78.9) 0.17 477 (77.3)
Prednisolone use currently, n (%) 6 (3.3) 43 (9.9) < 0.05 49 (7.9)
DMARD use currently, n (%) 22 (12.1) 225 (51.7) < 0.05 247 (40.0)
Biological agents, n (%) 1 (0.5) 10 (2.3) 0.13 11 (1.8)
† HLA-B27 determined in 322 cases. †† Radiographics obtained from 405 cases. * No statistics due to missing
values.
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PsA. As noted, the lack of universally agreed or validated
case definitions for PsA may be one reason for discrepancy
in the literature regarding prevalence.
The county of Hordaland has natural boundaries with
surrounding regions and has a stable population. Only resi-
dents of the county were included, and by using unique per-
sonal identification numbers we also identified residents of
the county that had attended Haugesund Rheumatism
Hospital, located south of the county. These factors
increased the sensitivity of identifying prevalent cases.
Based on thorough collection of data from patient records
we excluded patients that had been coded incorrectly as
PsA. A calculation of the positive predictive value of this
coding yielded 60.3%. By investigating a number of patients
(n = 100) coded with other arthritides, we calculated the
negative predictive value of the coding to be 99.0%.
Some factors in the study may have influenced an under-
estimation of prevalence. PsA is known for a variable clini-
cal course and may enter remission14. Thus some patients
may not have sought rheumatological attention during the
study period, and this may explain the lower prevalence
rates that we found in elderly patients. Cases with mild or
self-limiting arthritis may also not have been identified.
Arthritis that preceded psoriatic skin lesions would not be
recognized as PsA, and arthritis confined to the SI joints or
the spine remains unrecognized unless radiographic features
of SpA are assessed. We considered peripheral arthritis to be
present once a rheumatologist had diagnosed swollen and
tender joints, thus we may have included some patients with
self-limiting arthritis. This may conceivably have con-
tributed to overestimation of the prevalence of PsA. For a
small number of the prevalent cases the diagnosis of psoria-
sis had not been confirmed by a dermatologist. Assuming
that some of these did not have psoriasis, the effect on the
calculated prevalence rates would still be negligible due to
the small number of such patients. The finding of positive
RF in 4.1% of the cases is in agreement with studies of
blood donors at our clinic15, but RF positivity may also indi-
cate that some patients with RA were included. The use of
patient records gives data for both the cumulated disease
course and a cross-section at the last visit, but as a source for
radiographic data it reflects everyday practice, and this may
have influenced the assessment of an arthritis case as PsA,
AS, or OA. We found PsA confined to the SI joints or the
spine in only 2.7% of the cases, and there were fewer men
in this group than expected. This may be explained by the
fact that relatively few patients had been radiologically
assessed for SpA, and by a bias toward diagnosing men with
SpA with AS instead of PsA.
Considering this discussion, we believe our prevalence
rates are not likely to be biased to overestimation, and that
the true prevalence of PsA in our region is higher than indi-
cated in previous studies. The study of inflammatory joint
diseases in Finland7 reported an incidence of PsA about
two-thirds that of RA, which also indicates that PsA is more
common than previously documented.
According to both a Norwegian health interview survey16
and a study of a Norwegian Lapp population5, the overall
prevalence of psoriasis was 1.4%, with no difference
between men and women. Using the prevalence of PsA in
our study, the calculated prevalence of PsA among psoriatic
adults is 14%. In comparison, a Swedish study of psoriatics
who responded to a questionnaire found that 33% of patients
with psoriasis had previous or actual peripheral arthritis
and/or axial disease17, and a survey of members of the
Nordic Psoriasis Patient Organisation found that 33.8% of
the Norwegian members reported they had been diagnosed
with PsA by a rheumatologist or dermatologist6.
With increasing number of affected joints, the mean age
of the patients was higher and the mean disease duration
longer. This may reflect that patients who present with
mono- or oligoarthritis tend to evolve to polyarthritis over
time. Such a shift from oligo- to polyarthritis has been
described in other studies18,19. The inflammatory indicators
ESR and CRP were higher with longer disease duration, and
higher for patients with polyarthritis than for those with
mono- or oligoarthritis. This may indicate a higher general
disease activity over time as more joints are affected. The
distribution of the different subclasses of PsA in the study is
similar to previous findings18 where the patients had about
the same disease duration (12 years) as our patients. Our
findings of HLA-B27 must be interpreted with caution
because of missing data, but are in accord with studies that
showed that HLA-B27 is strongly associated with axial dis-
ease, but weakly with peripheral arthritis19.
Intraarticular injections of glucocorticoids had been
administered frequently to patients in our study. To our
knowledge this treatment method is not specifically studied
in PsA, but is mentioned in some textbooks and in a review
of treatment of PsA20. The use of such injections in arthritis
is described in a survey among Norwegian rheumatologists,
who generally consider this a very effective treatment with
few side effects21. The wide use of joint injections may be
seen in connection with a relatively low frequency of
DMARD use (40%). In 2 studies of early PsA22,23, DMARD
were used by 84% and 56% of the patients, respectively,
after 2 years’ disease duration. This difference may be relat-
ed to different study designs (prospective vs our cross-sec-
tional study) or to differences between patients with short
and long disease duration. In a comparable review of 221
outpatients with PsA with a median 10 years’ disease dura-
tion24, 47.5% of the patients used some DMARD, and this
is more in line with our findings. In contrast to these stud-
ies, where sulfasalazine and MTX were the most frequently
used DMARD, only 13.3% of the patients taking DMARD
in our study used sulfasalazine, while 70.5% used MTX.
This is in accord with a survey of rheumatologists in
Philadelphia, who ranked MTX as the most effective drug
1922 The Journal of Rheumatology 2005; 32:10
for treating peripheral PsA25. Few patients were treated with
biological agents; infliximab was introduced, and etanercept
was not yet approved for treating patients with PsA during
the study period.
We found a higher prevalence rate of PsA than previous-
ly reported. Polyarthritis was the most frequent subclass,
and the demographic data support the presence of a shift
from mono- and oligoarthritis to polyarthritis and increased
inflammatory activity with increasing duration of the dis-
ease. MTX was the most frequently used DMARD, and
patients were frequently treated with intraarticular injections
of glucocorticoids.
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Subjective Improvement in Patients with Psoriatic
Arthritis After Short-Term Oral Treatment with Seal Oil.
A Pilot Study with Double Blind Comparison to Soy Oil
TOR MAGNE MADLAND, TORMOD BJÖRKKJÆR, LINN ANNE BRUNBORG, LIVAR FRÖYLAND, 
ARNOLD BERSTAD, and JOHAN G. BRUN
ABSTRACT. Objective. To investigate effects of short-term oral treatment with seal oil in patients with psoriatic arthritis (PsA). 
Methods. Forty-three patients with polyarticular PsA were randomized to receive oral treatment for
2 weeks with either seal oil or soy oil in a double blind controlled trial. Clinical and biochemical
variables were assessed at baseline, after treatment, and 4 weeks post-treatment. Patients were
allowed to continue nonsteroidal antiinflammatory drugs (NSAID) and disease modifying
antirheumatic drugs (DMARD) during the study.
Results. Forty patients completed the study, 20 in each treatment group. Patients in the seal oil group
reported a significant improvement in global assessment of the disease 4 weeks post- treatment (p <
0.01), and both groups showed a trend toward improvement in tender joint count, but the differences
between the groups were not significant. There was a fall in the ratio of n-6 to n-3 fatty acids and in
arachidonic acid (AA) to eicosapentaenoic acid (EPA) in serum after treatment with seal oil (p <
0.01). Twenty-one percent of all patients had elevated values of calprotectin in feces suggestive of
asymptomatic colitis.
Conclusion. Treatment with seal oil was followed by a modest improvement in patient’s global
assessment of the disease and a trend towards a decrease in number of tender joints. There was a shift
in fatty acid composition in serum toward a putative antiinflammatory profile. Oral treatment with
seal oil may have NSAID-like effects in PsA. (J Rheumatol 2006;33:307–10)
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Psoriatic arthritis (PsA) belongs to the spondylo-
arthropathies (SpA), a group of inflammatory diseases with
common clinical and genetic characteristics. A significant
proportion of patients with SpA have evidence of gut
inflammation, and this has been suggested to play a patho-
genetic role1. Calprotectin has been recognized as a proin-
flammatory protein in arthritis and related conditions2, and
increased calprotectin levels in feces may serve as an indi-
cator of intestinal inflammation3. 
There is substantial evidence that dietary intake of fish
oil may have benefits in rheumatoid arthritis (RA), with
regard to both inflammation and collateral health4. Short-
term duodenal administration of seal oil to patients with
inflammatory bowel disease (IBD) and related joint pain
showed beneficial effects on joint pain in 2 recent studies5,6.
Fish oil has high amounts of the n-3 polyunsaturated fatty
acids (PUFA) eicosapentaenoic acid (EPA) and docosa-
hexaenoic acid (DHA). These have shown modulatory
effects on inflammation, mainly antiinflammatory7. On the
other hand, the n-6 PUFA arachidonic acid (AA) is a pre-
cursor of eicosanoids like prostaglandins, leukotrienes, and
related compounds with proinflammatory effects. The high
ratio of n-6 to n-3 fatty acids (FA) of the Western diet leads
to a high ratio of AA to EPA in blood and tissues, which
could promote arthritis by facilitating the production of
proinflammatory eicosanoids8. Of the n-3 PUFA, only EPA,
docosapentaenoic acid (DPA), and DHA are marine, i.e.,
naturally found in seafood and seafood products. Intake of
marine n-3 supplements may result in a decreased produc-
tion of AA-derived eicosanoids through several mecha-
nisms, including decreased availability of AA, competition
for cyclooxygenase (COX) and lipooxygenase (LOX), and
decreased expression of COX-2 and 5-LOX9. Fish oil and
seal oil have approximately the same total amount of n-3
PUFA, but seal oil has more DPA than fish oil. Although
there is slightly less EPA and DHA in seal oil than in fish oil,
intake of seal oil increases the serum level of EPA consider-
ably more than intake of fish oil10. The n-3 PUFA thus seem
to be more available from seal oil than from fish oil, possi-
bly by being located mainly in the middle position of the tri-
acylglycerol (TAG) molecule in fish oil, while located
almost exclusively in the 1 or 3 positions in seal oil TAG11.
Both pancreatic and lipoprotein lipases are position 1 and 3
specific12. In daily rheumatology practice we have noticed
that some patients use seal oil as a dietary supplement.
Based on the above observations, we investigated whether
short-term oral treatment with seal oil might have positive
effects on disease manifestations in patients with PsA.
MATERIALS AND METHODS
Patients with polyarticular PsA as diagnosed by a rheumatologist and seen
with active joint disease at our clinic during the last year were sent a writ-
ten inquiry to join the study. Polyarticular PsA was defined as polyarthritis
(5 or more swollen joints) in a patient with psoriasis, with seronegativity
for rheumatoid factor and absence of rheumatoid nodules. The sample
number (n = 40) was chosen to provide sufficient power to detect a differ-
ence of 10 mm on a 100 mm visual analog scale (VAS) for joint pain or
patient’s global assessment before and after treatment. Patients were
allowed to continue their usual medication including nonsteroidal antiin-
flammatory drugs (NSAID) and disease modifying antirheumatic drugs
(DMARD) during the study period. No patients changed their DMARD or
received intraarticular glucocorticoids within 4 weeks prior to study start.
The Regional Committee for Medical Research Ethics approved the study,
and all patients provided written informed consent before inclusion. 
Study design. Patients were assessed at the baseline visit, and if eligible for
the study, included and randomly allocated to treatment with either seal oil
(n = 22) or soy oil (n = 21). Ten milliliters of study oil was self-adminis-
tered orally before meals 3 times a day for 14 days. The patients were
reassessed at week 2 and week 6. All clinical assessments were made by the
same physician. The seal oil (Rieber Skinn A/S, Bergen, Norway) was
refined oil from harp seal (Phagophilus groenlandicus). Subjects in the seal
oil group thus received 2.4 g of EPA, 1.1 g of DPA, and 2.6 g of DHA per
day. Soy oil (Mills DA, Oslo, Norway) was selected as control treatment
based on its similarity to seal oil in consistency and appearance. The
received doses of soy oil correspond to 14.9 g of linoleic acid (LA) per day.
The FA profiles of seal oil and soy oil are presented in Table 1.
Assessments. Joint pain intensity (VAS) and the patient’s global assessment
of the disease (VAS) were chosen as primary efficacy measures based on
results from earlier studies with seal oil in IBD-related joint pain5,6 and the
short duration of the present trial. The numbers of tender and swollen joints
were also assessed at all visits (EULAR 44 joints13 and distal interpha-
langeal joints of fingers totalling 52 joints). Skin manifestations were
assessed using the PASI score (Psoriasis Area Severity Index)14. Humoral
biomarkers of arthritis activity were C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR) according to Westergren method, and calpro-
tectin2, which was analyzed by ELISA (Ullevål University Hospital, Oslo,
Norway). As a measure of intestinal inflammation, we determined the con-
centration of calprotectin in feces3, using the Nycotest Phical ELISA kit
(Nycomed, Norway). We also determined the serum concentration of cho-
lesterol and homocysteine (Laboratory of Clinical Biochemistry,
Haukeland University Hospital). FA compositions in serum and treatment
oils were analyzed by gas liquid chromatography (Auto-GC) according to
the described method6.
Statistics. Statistical analyses were performed using SPSS release 13.0 soft-
ware (SPSS Inc., Chicago, IL). For normally distributed data we used mean
and standard deviation (SD) or median and range. We used the paired sam-
ples t test or Wilcoxon sign rank test for changes from baseline within
groups, and the t test or Mann-Whitney test for comparisons between
groups. Since we analyzed multiple variables, p values < 0.01 were con-
sidered statistically significant. Monovariate associations between vari-
ables were analyzed using the Spearman rank order correlation test.
RESULTS
Forty-three patients were included between October 2003
and January 2004. Three subjects did not complete the trial:
one because of a sports injury (seal oil), one because of
intolerance to the study oil (seal oil), and one gave no rea-
son for dropping out (soy oil). Baseline characteristics of the
patients are presented in Table 2. The treatment groups were
comparable regarding gender, age, disease duration, self-
reported dietary intake of fish or fish oil, and mean ratio of
n-6 to n-3 PUFA in serum. There were no significant differ-
ences in disease assessment variables between the groups at
baseline, nor in concomitant medication with NSAID. More
patients in the soy oil group were receiving some DMARD,
but the difference between the groups was not significant (p
= 0.05). The mean concentration of calprotectin in feces was
equal: 21% of all patients had values above the upper refer-
ence value (50 mg/kg). The acute phase reactants (ESR,
CRP, and calprotectin in plasma) were correlated at baseline
(p < 0.05), but calprotectin was the reactant with the
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Table 1. Fatty acid profiles of seal oil and soy oil (g/100g).
Seal Oil Soy Oil
Total saturated 14.2 13.4
Total monoenes 48.9 19.0
18:2n-6 (LA) 1.5 49.7
20:4n-6 (AA) 0.6 nd
Total n-6 2.2 49.7
18:3n-3 (ALA) 0.6 5.5
20:5n-3 (EPA) 7.9 nd
22:5n-3 (DPA) 3.7 nd
22:6n-3 (DHA) 8.6 nd
Total n-3 23.9 5.5
n-6/n-3 0.1 9.0
LA: linoleic acid; AA: arachidonic acid; ALA: α-linolenic acid; EPA:
eicosapentaenoic acid; DPA: docosapentaenoic acid; DHA: docosa-
hexaenoic acid; nd: not detected.
Table 2. Baseline characteristics of study patients.
Seal Oil Soy Oil
(n = 20) (n = 20)
Female/Male 10/10 12/8
Age, mean (± SD) 56.9 (11.5) 53.0 (10.6)
Disease duration, yrs, median (range) 11.5 (0.5–27) 14.5 (3–30)
PASI score (0–72), median (range) 1.6 (0–11.2) 4.4 (0–14.3)
Calprotectin in feces mg/kg (0–50), 34.9 (34.1) 25.4 (16.6)
mean (± SD)
NSAID therapy, n (%) 17 (85) 17 (85)
DMARD therapy, n (%) 8* (40) 15** (75)
Erosive disease, hands/feet, n (%) 10 (50) 13 (65)
Ratio n-6 to n-3 PUFA in serum, mean (± SD) 7.2 (2.4) 6.9 (3.1)
* DMARD: methotrexate 4, sulfasalazine 1, hydroxychloroquine 1. ** DMARD:
methotrexate 9, leflunomide 3, sulfasalazine 2, methotrexate + sulfasalazine 1.
strongest correlation with an outcome variable; the tender
joint count (p < 0.05). Values of CRP lower than 10 mg/l
were not quantified. As this was the case for most patients,
CRP was omitted as an assessment variable. Results of other
assessment variables for the treatment groups are presented
in Table 3. The seal oil group reported a tendency towards
improvement in global assessment at week 2, and reached a
significant level of improvement at week 6 (p < 0.01). This
group showed a trend toward a decrease in the number of
swollen joints at week 6 (p < 0.05), and both groups had a
reduction in the number of tender joints at week 6 (p < 0.05).
There were no significant differences between the groups
after treatment, and the degree of psoriasis was unchanged
according to the PASI score. Two patients (one from each
treatment group) reported symptoms consistent with respira-
tory tract infection and had increased CRP and ESR at week
2, with spontaneous recovery at week 6. Table 4 shows the
serum values for cholesterol, homocysteine, and FA during
the study. The seal oil group had a significant rise in serum
concentration of EPA and fall in the ratio of AA to EPA and
n-6 to n-3 PUFA after treatment (p < 0.01). The soy oil group
had a reduction in both total and low density lipoprotein cho-
lesterol and an increase in LA and α-linolenic acid (p < 0.01).
Significant group differences were found for the changes in
FA concentrations (p < 0.01). After finishing the study, 25
patients (62.5%) correctly identified which oil they had
received according to taste, smell, or consistency.
DISCUSSION
Our finding of a significant but modest improvement in
patient’s global assessment after oral treatment with seal oil
is in agreement with studies of treatment effects of fish oil
in RA4 and seal oil in patients with IBD-related joint pain5,6.
Patients treated with seal oil in our study reported an
improvement in global assessment of disease but less reduc-
tion of joint pain. The treatment may have relieved symp-
toms that we did not record, like stiffness and fatigue, or the
treatment period may have been too short to achieve signif-
icant reduction of joint pain. The rapid effect in the 2 latter
studies may be related to duodenal rather than oral adminis-
tration of the seal oil. Duodenal administration might ensure
a more rapid absorption by yielding a higher bolus of n-3
PUFA into circulation when administering the oil to the
major site of TAG hydrolysis, thus avoiding mixing and
dilution in the stomach. Despite lower increase in serum
values of n-3 PUFA than Bjorkkjaer, et al reported6, we
clearly showed absorption of FA from seal oil into the cir-
culation. A shift in FA composition in serum may occur
more rapidly after seal oil than fish oil treatment because of
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Table 3. Results of assessment variables for the treatment groups. Results are expressed as median (range). No significant differences between the groups
were detectable before and after treatment (Mann Whitney test).
Seal Oil Soy Oil
Baseline Week 2 Week 6 Baseline Week 2 Week 6
Patient’s global assessment, mm 47 (10–97) 33.5 (4–97) 33 (2–85)* 41.5 (2–81) 33 (1–80) 36.5 (2–71)
Joint pain intensity, mm 35.5 (13–72) 45.5 (3–84) 31 (5–78) 35 (11–69) 37.5 (1–76) 36.5 (2–66)
MHAQ (1–4) 1.7 (1–2.5) 1.7 (1–2.6) 1.6 (1–2.8) 1.5 (1–2.3) 1.4 (1.1–2.3) 1.4 (1–2.2)
Tender joint count (0–52) 9 (0–37) 7.5 (0–37) 5 (0–29) 10.5 (2–29) 8 (0–29) 7 (0–26)
Swollen joint count (0–52) 2 (0–11) 2.5 (0–8) 1.5 (0–6) 2 (0–10) 2 (0–13) 2 (0–12)
ESR, mm/h 8.5 (1–39) 9 (1–39) 9 (1–44) 10 (1–32) 12 (1–42) 9 (1–61)
Calprotectin, mg/l (100–900) 740 (460–3460) 880 (500–4780) 1000 (360–6640) 1000 (360–5360) 820 (400–4360) 880 (320–7080)
* p < 0.01, changes from baseline within group (Wilcoxon sign rank test).
Table 4. Mean (SD) serum values of cholesterol, homocysteine and fatty acids (expressed as mg/g) for the treatment groups.
Seal Oil Soy Oil
Baseline Week 2 Week 6 Baseline Week 2 Week 6
Total cholesterol, mmol/l 5.5 (1.2) 5.4 (1.1) 5.5 (1.0) 5.8 (0.8) 5.4 (0.8)* 5.9 (0.9)
HDL-cholesterol, mmol/l 1.5 (0.6) 1.6 (0.7) 1.5 (0.5) 1.6 (0.4) 1.6 (0.4) 1.6 (0.4)
LDL-cholesterol, mmol/l 3.5 (1.0) 3.4 (0.8) 3.3 (0.9) 3.8 (0.7) 3.5 (0.7)* 3.9 (0.9)
Homocysteine, µmol/l 12.0 (3.1) 12.7 (3.0) 12.4 (3.2) 10.3 (4.1) 10.0 (2.7) 9.8 (2.9)
Linoleic acid** 1.83 (0.48) 1.60 (0.53) 1.72 (0.52) 1.41 (0.33) 1.79 (0.40)* 1.66 (0.51)
α-linolenic acid** 0.04 (0.17) 0.05 (0.05) 0.05 (0.03) 0.03 (0.02) 0.04 (0.01)* 0.04 (0.03)
Arachidonic acid 0.32 (0.12) 0.27 (0.11) 0.27 (0.11) 0.25 (0.06) 0.26 (0.05) 0.27 (0.05)
Eicosapentaenoic acid** 0.09 (0.08) 0.35 (0.19)* 0.13 (0.08) 0.08 (0.06) 0.08 (0.04) 0.09 (0.06)
Docosapentaenoic acid 0.03 (0.02) 0.05 (0.03) 0.04 (0.02) 0.03 (0.02) 0.03 (0.02) 0.03 (0.01)
Docosahexaenoic acid 0.19 (0.09) 0.26 (0.11) 0.21 (0.08) 0.15 (0.06) 0.15 (0.05) 0.16 (0.05)
n-6/n-3 fatty acids** 7.2 (2.4) 3.1 (1.3)* 5.4 (1.4) 6.9 (3.1) 7.5 (2.5) 7.2 (3.6)
AA/EPA 4.7 (2.2) 1.0 (0.7)* 2.8 (1.6) 5.4 (5.1) 4.3 (2.3) 5.5 (4.7)
* P < 0.01, changes from baseline within group (paired samples t test). ** Significant differences between the groups from week 0 to week 2 (t test, p < 0.01).
the conformity between positioning of the n-3 PUFA in the
TAG molecules in seal oil and the specificity of the human
lipases. Readily available free n-3 PUFA from seal oil may
compete with AA and inhibit its metabolism to eicosanoid pro-
duction. The PUFA are distributed to and incorporated into
cellular membranes throughout the body, and may thereafter
be released to generate eicosanoid mediators. This may be one
mechanism explaining the beneficial effects of the treatment
for several weeks post-treatment, as in our study, and months
as recorded by Bjorkkjaer, et al6. Mechanisms for antiinflam-
matory effects of n-3 PUFA have been described7-9.
Based on earlier studies of treatment effects of fish or
seal oil and the short duration of our study, we looked pri-
marily for symptomatic, NSAID-like effects. Hence, the use
of major response criteria for clinical trials such as the pso-
riatic arthritis response criteria (PsARC), American College
of Rheumatology (ACR) criteria, or disease activity scores
(DAS) did not seem appropriate. Instead, we assessed
several clinically relevant variables, looking for short-term
responses to the intervention, with special emphasis on
detecting differences in subjective measures. 
Patients were allowed to continue NSAID during the
study period, and since both n-3 PUFA and NSAID have
effects on eicosanoid production through the COX pathway,
there is a possibility of interaction. Treatment with FA would
have to show effects in addition to those of the NSAID used.
Therefore a treatment effect may have been masked. 
The fact that only slightly more than 50% of the patients
were able to identify which treatment they had received
indicates that there was no significant blinding bias. It may
be questioned whether soy oil constitutes a valid compari-
son to seal oil. Since soy oil contains n-6 PUFA, which may
affect eicosanoid production, soy oil should not be regarded
as a true placebo treatment.
Patients included in the study were homogenous in terms
of clinical presentation of PsA with polyarthritis. This was
decided in order to overcome the complex outcome measure
of axial disease and oligoarthritis, which are other clinical
presentations of PsA. The study patients generally had low
disease activity as measured with PASI score, number of
swollen joints, ESR, and CRP. This may have limited the
potential for recording improvement by any treatment. Most
patients had normal CRP values, and we therefore also
measured inflammatory activity by use of calprotectin. This
protein has been shown to be a good indicator of disease
activity in various inflammatory rheumatic diseases, espe-
cially in RA15. In PsA calprotectin has been found in ele-
vated concentrations both in the synovial membrane and in
serum, the latter with significant correlations with systemic
variables of disease activity16. We also found high correla-
tions between the inflammatory markers ESR, CRP, and cal-
protectin in the serum of the study patients. Our finding of
high levels of calprotectin in feces of patients with PsA
without symptoms suggesting IBD is in accordance with
previous reports17, and indicates that some patients with
PsA may have asymptomatic colitis.
In conclusion, we showed a shift in FA composition in
serum after treatment with seal oil compared to soy oil towards
a putative antiinflammatory profile. Patients treated with seal
oil reported a subjective improvement of disease as opposed to
patients treated with soy oil, but the difference between the
groups was not significant. The results warrant further studies
of longer duration and more participants to characterize the
magnitude and quality of the treatment effects. 
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Leukocyte protein calprotectin and outcome in rheumatoid
arthritis
A longitudinal study
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Objective: To determine if calprotectin is predictive for outcome in patients with rheumatoid arthritis (RA).
Methods: Fifty six RA in-patients with variable disease duration were prospectively followed for ® ve years. Clinical and laboratory data
were collected to assess disease activity. Health Assessment Questionnaire (HAQ) and radiographic scores (of hands and wrists) as described
by Larsen were used as outcome measures. Plasma calprotectin levels were determined with ELISA technique.
Results: Signi® cant correlations (r) were found cross-sectionally at follow-up between calprotectin concentration and other known
parameters of disease activity and severity: CRP (r= 0.67), investigator’s global assessment of disease activity (r= 0.57), Waaler titre
(r= 0.50), HAQ score (r= 0.48) and number of swollen joints (r= 0.48). Calprotectin at baseline was not identi® ed as an independent
predictor for HAQ or radiographic progression in the multivariate analysis.
Conclusion: The results con® rm calprotectin as a good measure of disease activity and joint in¯ ammation in RA. However, the level of
calprotectin at baseline was not predictive for radiographic damage or functional impairment ® ve years later.
Key words: calprotectin, rheumatoid arthritis, prognostic factors, radiographic damage
Calprotectin is a leukocyte derived protein that seems
to regulate intracellular functions and have extracellu-
lar immunomodulating properties (1). Plasma levels
rise in response to various tissue injuries (2) and
in¯ ammation (3). Calprotectin was described in 1980
by Fagerhol et al (4) as the L1 protein, and was found
to bind calcium. The name calprotectin was proposed
(5), re¯ ecting its protective role in epithelial defense (6,
7), and fungicidal, bactericidal and antiin¯ ammatory
effects (5, 8 ± 10). Subsequently, the protein has been
studied in rheumatic diseases, but also in a number of
other clinical conditions. In faeces, the concentration
of calprotectin is risen in patients with in¯ ammatory
bowel disease (11) and in those with colorectal cancer
(12), showing potential as a tool in the diagnosing and
follow-up of these conditions (13). The plasma level of
calprotectin is increased in cystic ® brosis (14) and other
conditions with reduced pulmonary gas diffusion (15).
Furthermore, calprotectin has been documented to
promote neurite outgrowth (16).
Studies of calprotectin in patients with rheumatoid
arthritis (RA) has described increased concentrations
in circulating leukocytes (17), in synovial neutrophil
leukocytes (18) and in synovial ¯ uid (19). The
plasma level of the protein correlates with C-reactive
protein (CRP) and other disease variables (20 ± 22)
which have been associated with an unfavourable
outcome in RA (23, 24). Also in juvenile rheumatoid
arthritis (25), reactive arthritis (26), and in systemic
lupus erythematosus (27), calprotectin seems to be a
marker of joint in¯ ammation. In patients with SjoÈ gren’s
syndrome (SS) salivary calprotectin correlates with
variables of SS glandular pathology (28), suggesting
that the protein levels in saliva may be a marker of
the local SS disease activity.
Guide lines for the treatment of RA points to early
and effective treatment of synovitis as essential in
order to reduce joint damage and functional disability
(29). However, there are subgroups of patients with a
good prognosis that should not be over-treated, thus
there is a need for predictors for outcome giving basis
for treatment decisions. Several prognostic factors
are identi® ed, as reviewed in (30), but still the disease
outcome in an individual patient with early RA is
dif® cult to predict by present means.
As described, the plasma calprotectin correlates
with disease parameters that are associated with an
unfavourable outcome of RA. On the other hand,
calprotectin inhibits immunoglobulin production of
B-cells in vitro (31). In a rat model calprotectin was
found to protect against the development of arthritis
(10). It has also been shown that calprotectin may
inhibit metalloproteinases (32, 33). These ® ndings
suggest that calprotectin has a protective role in
arthritis or that levels rise in response to tissue
injury. Because of calprotectin’ s putative protective
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effects and association with prognostic markers in
RA, we wished to examine this protein prospectively
as a possible independent predictor of joint damage
and functional disability in RA.
Patients and methods
Patients
Consecutive patients with RA according to The
American Arthritis Association (ARA) criteria (34)
admitted to our in-patient clinic were examined in
1992. There were various reasons for admission, the
most common being starting or changing of drug
treatment for RA. The patients were reassessed ® ve
years later, and the resulting study group consisted
of 56 subjects.
Clinical and biological assessments
The following evaluation data were collected at
baseline and follow-up: Disease duration, number of
swollen and painful joints (56 joint-count), pain last
week (on a visual analogue scale, VAS), duration of
morning stiffness, patient’s and investigator’s overall
assessment of disease activity (VAS), a translated
version of the Health Assessment Questionnaire
(HAQ) (35), CRP and erythrocyte sedimentation
rate (ESR). Joint status was performed by one
investigator at baseline and another at follow-up.
The titre of RF was determined by Waaler’s test, and
we used a cut-off value of 128 for a positive RF.
Plasma collected at baseline was stored at ± 80³
Celcius, and calprotectin was determined in these
samples in parallell with the samples from follow-up
by use of ELISA as previously described (22, 36)
Radiographic measurement
Radiographs of hands and wrists were obtained at
baseline and after ® ve years. They were evaluated by
a radiologist blinded for time sequence and scored
according to the Larsen method (37).
Statistical methods
The statistical analyses were performed using SPSS
Release 9.0.0 software (SPSS Inc., Chicago, IL,
USA). Data were frequently not normally distrib-
uted and we used the median and the interquartile
range as measures of central tendency and disper-
sion. Differences between groups were tested with
the Wilcoxon signed rank test. Monovariate associa-
tions between variables were analysed using the
Spearman rank order correlation test. Larsen score
high ( ³ the median value)/low and HAQ score high
( ³ the median value)/low were considered as out-
come variables. Baseline predictive factors for out-
come were studied using multiple logistic regression
with a forward stepwise design. Logistic regression
was also used in the cross sectional multivariate
analyses.
Results
The study group of 56 subjects contained 38 women
and 18 men. At inclusion, the median age was
63 (interquartile range 50.3 ± 70.8) years, and the
median disease duration was 7.8 (2.3 ± 19.4) years.
Thirthy-four percent of the patients were RF
positive at inclusion, and 46% at follow-up. Low
dose peroral steroids were used by 25 (45%) patients
at inclusion and by 23 (42%) at follow-up. Disease-
modifying antirheumatic drugs were used by 42
patients (75%) at inclusion and by 35 patients (63%)
at follow-up.
Longitudinal data
Disease variables as ESR, calprotectin, number of
tender joints, investigator’s global assessment of
disease activity, HAQ score and duration of morning
stiffness decreased during the study period. The
Larsen score increased, and a non-signi ® cant increase
was noted for the number of swollen joints during
the period (Table I). Eight patients at inclusion and
® ve patients at follow-up had a Larsen score of zero.
Calprotectin level at baseline did not correlate
signi® cantly with the Larsen score (r= 0.24) or the
HAQ (r= 0.18) at follow-up (p= 0.08 and 0.19
respectively). The correlation between baseline cal-
protectin and radiographic progression de® ned as
increase in Larsen score over the ® ve years (r= 0.17)
was also not signi® cant (p= 0.25). In the logistic
regression analysis calprotectin was not identi® ed as
an independent predictor of radiographic progres-
sion or HAQ.
Cross sectional associations between variables at
follow-up
Calprotectin was highly correlated with CRP, and
both calprotectin and CRP had high correlations
with the Larsen score. Calprotectin, ESR and CRP
had high correlations also with the HAQ score
(Table II). Multivariate logistic regression analysis
showed that the duration of morning stiffness, investi-
gator’ s assessment of disease activity, and calpro-
tectin were independently associated with the Larsen
score. The number of swollen joints, patient’s and
investigator’s assessment of disease activity, and the
Tor Magne Madland et al.
352
Larsen score were independently associated with the
HAQ score.
Discussion
Calprotectin is comparable with CRP as a marker of
disease activity in RA, and correlates with arthritis
activity in cross sectional studies (21, 22). This was
con® rmed in the present study (Table II). Most varia-
bles re¯ ecting disease activity were higher at baseline
than at follow-up. This may in part be due to the
study design with inclusion of patients needing
hospitalisation, thus creating a bias towards higher
disease activity at inclusion with regression towards
the mean at follow-up.
We are not aware of other studies investigating
calprotectin prospectively with regard to outcome in
RA. The joint damage assessed by Larsen score is a
direct and objective outcome measure in RA,
representing a cumulative result of the disease, but
is independent of the current disease activity. This
damage is accompanied by functional impairment of
the patient (38), although the HAQ score also may
be in¯ uenced by the disease activity (39). On this
background radiographic progression and HAQ
score are relevant outcome variables when studying
calprotectin as a prognostic factor. It might be
questioned whether a single analysis of calprotectin
could predict some clinical outcome in RA, but for
other in¯ ammatory markers as CRP and ESR this
has been documented (40).
Calprotectin at baseline correlated only weakly
with the radiographic progression, and was not
identi® ed as an independent predictive factor for
joint damage in the logistic multivariate analyses.
This result should be interpreted with some caution
since the study group was relatively small and
because some patients had longer disease duration at
baseline. This fact could in¯ uence on the radio-
graphic progression since most of the erosions come
early in the disease and there is a ceiling effect of
developing erosions in established disease (41).
In conclusion, this and previous studies show that
calprotectin is a good measure of disease activity in
RA, but calprotectin did not behave as a predictor of
joint damage or functional impairment in the present
study.
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ABSTRACT 
Background. Biomarkers of inflammatory diseases are studied for their usefulness in 
monitoring treatment of rheumatoid arthritis (RA). The advantage of each candidate marker is 
not clearly defined. Progress in treatment options may shift the goals of successful treatment 
to include preventing concomitant manifestations of RA. 
Objectives. The aim of the study was to examine the relationship of S100A12 serum 
concentration to RA disease activity, extra-articular manifestations (ExRA) and concomitant 
cardiovascular (CV) disease. The performances of rheumatoid factor (RF), anti-CCP, 
calprotectin and CRP to the same clinical measurements were included for comparison. 
Methods. RA patients (n=129) were clinically assessed for disease activity and the presence 
of ExRA and CV disease. Serum concentrations of the potential biomarkers were compared 
with clinical diagnoses by correlation and regression. S100A12 and RF were examined in 
multiple logistic regressions with ExRA and CV disease, respectively. 
Results. Among the 129 patients 43 (33.3%) had ExRA and 17 (13.2%) had CV disease. 
Serum concentrations of S100A12 correlated significantly with all performed measurements 
of RA disease activity (p<0.01) although weaker than for CRP and calprotectin. The serum 
level of S100A12 was stronger associated to ExRA (OR 1.664, p=0.003) than was the RF titre 
(OR 1.206, p=0.009). 
Conclusions. Measurement of S100A12 and RF may identify RA patients with a less 
favourable prognosis. CRP seems to have slightly better performance than calprotectin and 
S100A12 with regard to RA disease activity. 
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S100 Proteins Calprotectin and S100A12 Are Related to
Radiographic Changes Rather Than Disease Activity in
Psoriatic Arthritis with Low Disease Activity
TOR MAGNE MADLAND, ANNETTE LARSEN, and JOHAN G. BRUN
ABSTRACT. Objective. To investigate serum levels of calprotectin (S100A8/S100A9) and S100A12 as markers of
disease activity or distinct clinical or radiographic features in patients with psoriatic arthritis (PsA).
Methods. Serum levels of calprotectin and S100A12, erythrocyte sedimentation rate (ESR), and C-reac-
tive protein (CRP) were determined in 119 patients with PsA. Correlations to clinical variables were cal-
culated, and subgroups of patients were compared.
Results. The correlations to clinical disease activity measures were stronger for CRP than for ESR and
calprotectin. In the regression analysis, calprotectin was identified as an independently associated fac-
tor for presence of peripheral radiographic features of arthritis (OR 1.33, 95% CI 1.01–1.76). S100A12
levels were also elevated in those with peripheral radiographic features (p = 0.036), but did not corre-
late with clinical variables of disease activity.
Conclusion. Calprotectin and S100A12 do not perform better than traditional biomarkers of disease
activity in PsA, but were associated with presence of peripheral radiographic features in this cross-sec-
tional study. The patients’ low level of disease activity may have led to underestimation of the associa-
tions between any biomarker and disease measures. (First Release Sept 1 2007; J Rheumatol
2007;34:2089–92)
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Psoriatic arthritis (PsA) is a chronic inflammatory joint dis-
ease with both similarities to rheumatoid arthritis (RA) and
distinct clinical features of its own. Unlike in RA, the ery-
throcyte sedimentation rate (ESR) and C-reactive protein
(CRP) biomarkers are generally not as reliable as disease
activity measures in PsA1, and normal levels were reported as
a feature with discriminative value toward RA in the CASPAR
study2. Consequently, it would be of interest to identify novel
biomarkers for assessing disease activity and response to ther-
apy in PsA. The leukocyte protein complexes calprotectin
(S100A8/S100A9, MRP8/MRP14, or calgranulin A and B)
and S100A12 [EN-RAGE (receptor for advanced glycation
endproducts) or calgranulin C] belong to the family of S100
proteins and have both intracellular and extracellular
immunoregulatory functions3. These protein complexes have
been referred to as proinflammatory proteins in arthritis, and
have been proposed to be superior to conventional biomarkers
of inflammation with closer correlation to disease activity4.
Plasma concentrations of calprotectin reflect disease activity
in RA5,6 as well as in PsA7,8. S100A12 exerts effects through
interaction with RAGE followed by activation of the nuclear
factor-κB system and of endothelial cells9. In PsA, increased
levels of S100A12 as well have been described in peripheral
blood, synovial fluid, and synovial tissue10-12. In a gene
expression study, S100A8 and S100A12 were among the
upregulated genes that identified a unique pattern differentiat-
ing PsA from RA and from healthy controls13. We investigat-
ed whether serum levels of calprotectin or S100A12 reflect
the disease activity and distinct clinical or radiographic fea-
tures in a population of patients with PsA.
MATERIALS AND METHODS
We enrolled 119 patients with PsA, defined as presence of peripheral arthritis
or radiological evidence of spondyloarthritis in a patient with psoriasis.
Details of the case definitions and disease manifestations of the PsA popula-
tion from which we recruited are reported14. To select cases from our PsA
population with active disease, an inquiry to be assessed was sent to those
who during the previous year had attended our clinic with axial symptoms or
at least one swollen joint. For the same reason, patients treated with tumor
necrosis factor-α (TNF-α) blockers were excluded, as were patients with any
infectious disease or surgical interventions or who had received intraarticular
glucocorticoids during the previous month. Responders to the inquiry were
interviewed and clinically assessed, and radiographs of hands, feet, pelvis,
and the lumbar spine were obtained if not performed within the previous year.
The Regional Committee for Medical Research Ethics approved the study,
and all patients provided written informed consent.
The numbers of tender and swollen joints were assessed by use of the
EULAR 44-joint count including distal interphalangeal joints of fingers,
yielding 52 joints. Skin manifestations were assessed using the Psoriasis Area
Severity Index (PASI)15. The patient’s global assessment of disease activity
and pain intensity in the last week were recorded on a visual analog scale
(VAS), and physician’s global assessment of disease activity on a 5-point
Likert scale. The Modified Health Assessment Questionnaire (MHAQ) was
used as a functional disability score16. Radiographs of hands and feet were
assessed by radiologists in a clinical setting for features of arthritis such as
erosions, osteolysis, and bony proliferations, whereas isolated soft tissue
swelling or joint space narrowing was not considered.
Laboratory data included ESR, CRP, HLA-B27 typing, and Waaler test
for rheumatoid factor (cutoff titer ≥ 128). Serum samples were also assayed
by ELISA for calprotectin17 and S100A1218. According to analyses of blood
donation samples, the reference intervals in serum are 0.51–4.10 mg/l for cal-
protectin and 0.04–1.57 mg/l for S100A1218.
Statistical analyses were performed using SPSS software (SPSS, Chicago,
IL, USA). Spearman correlation coefficients were used to study univariate
associations between different variables. The Mann-Whitney test was used to
compare subgroups of patients. To test for associations between biomarkers
and radiological change we used multiple logistic regression analyses with
forward stepwise design.
RESULTS
Patients’ demographic and clinical characteristics are summa-
rized in Table 1. Median values of the disease variables
recorded and the correlations between these are presented in
Table 2. CRP was more strongly correlated to clinical disease
activity measures than were ESR and calprotectin, and serum
levels of S100A12 did not correlate. Except for ESR and
S100A12, the levels of the biomarkers were intercorrelated.
As expected, patients with many swollen joints or high disease
activity according to the physician’s global assessment had
higher levels of ESR, CRP, and calprotectin compared to those
with low disease activity or few swollen joints (Table 3). The
levels of biomarkers were not affected by the PASI score or
the accumulated number of affected joints, but CRP was sig-
nificantly higher in patients with spondyloarthritis. Levels of
both calprotectin and S100A12 were higher in patients with
peripheral radiographic features of arthritis than in those with-
out. In the logistic regression analysis, with radiographic fea-
tures in hands or feet as the dependent variable, calprotectin
was identified as independently associated with the presence
of radiographic features (OR 1.33, 95% CI 1.01-1.76).
DISCUSSION
We did not identify calprotectin or S100A12 as better bio-
markers of disease activity than ESR and CRP in PsA. For cal-
protectin, this is consistent with results from 2 previous stud-
ies with fewer patients7,8. S100A12 did not behave as an
inflammatory biomarker — this is in contrast to the report of
high correlations between serum S100A12 and disease activi-
ty measures in a small number of patients with PsA, as well as
responsiveness to treatment with methotrexate10. The serum
concentrations of calprotectin and especially S100A12 were
less elevated than in patients with RA that we have studied
(unpublished observations), and such differences have been
reported for calprotectin7 and for S100A1210,11. A more sys-
temic inflammation in RA than in PsA might be part of the
explanation for this, possibly with a more activated endotheli-
um in RA facilitating the release of calprotectin and S100A12.
The concentrations of S100 proteins in our study and the
above noted groups are not to be compared directly, since no
common standard has been used.
The associations between serum levels of calprotectin and
S100A12 and peripheral radiographic features in PsA are new
observations. Calprotectin and S100A12 were both better
indicators for any peripheral radiographic features than ESR
and CRP in the univariate analysis. In the multivariate regres-
sion analysis, we identified the concentration of calprotectin
as an independently associated factor for the presence of
peripheral radiographic features of arthritis. An association
between calprotectin level and joint damage has recently been
described in a study of RA19. The cross-sectional design of
that study and our own presupposes that a single serum analy-
sis of an inflammatory protein may relate to cumulated radi-
ographic features. Although such a relationship has been doc-
umented for CRP in RA20, our study design did not allow con-
clusions about the prognostic value of calprotectin and
S100A12. Future prospective studies are warranted to address
this. Another limitation is the low disease activity of our
patients. Although we intended to select patients from our PsA
population with active disease, the median values of all bio-
markers assessed were within the reference values. Treatment
with prednisolone, disease modifying antirheumatic drugs, or
biologic therapy may significantly suppress the disease activ-
ity, and this constitutes a methodological problem in studying
associations between inflammatory biomarkers and outcomes
in general. By excluding patients undergoing treatment with
TNF-α blockers this bias is expected to be reduced. The low
disease activity may have led to underestimation of the asso-
ciations between any biomarker and disease measures. The
patient characteristics for age, disease measures, sex, and
rheumatoid factor positivity were comparable to those of the
CASPAR study2, but we included a larger proportion of
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Table 1. Characteristics of the patients (N = 119). Data are mean (range)
for continuous variables and number (%) for categorical variables.
Age, yrs 52.5 (22–74)
Disease duration, yrs 12.4 (0.5–39)
Male 61 (51.3)
Polyarthritis 91 (76.5)
Mono- or oligoarthritis 23 (19.3)
Spondyloarthritis exclusively 5 (4.2)
Radiographic signs of SpA (n = 93 pts) 26 (21.8)
Radiographic changes of hands/feet (n = 107) 57 (47.8)
HLA-B27-positive (n = 113) 25 (22.5)
Rheumatoid factor-positive 5 (4.2)
Patient treatment
Nonsteroidal antiinflammatory drug 87 (73.1)
Disease modifying antirheumatic drug 56 (47.1)
Methotrexate 42 (35.3)
Prednisolone 8 (6.7)
patients with polyarthritis than with mono- or oligoarthritis
compared to the general PsA population at our clinic14.
Immunohistological studies have described higher levels of
expression of calprotectin (MRP8/MRP14) in synovium from
patients with PsA compared to RA, and particularly in
perivascular areas of the synovial sublining layer8. Synovial
expression of S100A12 is also increased in PsA and RA10,12.
Consequently, these authors point to a possible role for
S100A12 in the angiogenesis and altered function of
microvascular endothelium that has been reported in the syn-
ovitis of PsA21. Together, our observation of association
between these S100 proteins and peripheral radiographic fea-
tures and the previous reports of synovial perivascular expres-
sion indicate that S100 proteins are to some extent involved in
or serve as markers of the joint destruction in PsA. To further
investigate pathogenetic and clinical implications of calpro-
tectin and S100A12, both immunohistological and prospec-
tive clinical studies of early PsA are needed.
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